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Atopic dermatitis (= atopic eczema) is a common skin disease characterised by 
eczema, a superficial inflammation of the skin, and impaired function of the 
epidermal barrier. Patients also are at an increased risk for asthma and allergic 
rhinitis. Development of these atopic diseases in childhood is often referred to as 
the “atopic march”. As atopic dermatitis is a chronic disease, treatment modalities 
must be planned long-term. Treatment with tacrolimus ointment has shown good 
efficacy and safety in long-term studies in adults and in children over 2 years old. 
Since topical tacrolimus treatment targets the T cells in the skin, long-term safety 
in terms of skin infections and skin cancer has been of special interest. 
The aim of this thesis was to further study the long-term efficacy and safety of 
treatment with tacrolimus ointment in atopic dermatitis, also in comparison to 
topical corticosteroid treatment. Two studies focused on cell-mediated immunity 
of the skin and one of them in addition on epidermal barrier function. Respiratory 
symptoms in patients with atopic dermatitis initially treated long-term with tac-
rolimus ointment were evaluated in a 10-year follow-up study. Effective treatment 
of atopic dermatitis is especially important in infants to minimise sensitisation 
through the skin and thus possibly stop the atopic march, so two studies in chil-
dren under 2 years of age investigated the pharmacokinetics, safety, and efficacy of 
their treatment with 0.03% tacrolimus ointment.
Adults or adolescents with moderate-to-severe atopic dermatitis were evaluated in 
three clinical studies and infants with atopic dermatitis in two clinical studies. In 
Study I, 48 patients, participating in a 4-year open safety study of 0.1% tacrolimus 
ointment, were tested for recall antigen reactivity at baseline and after 12 months 
of treatment. In addition, 28 healthy controls were tested. Study II was a long-term, 
double-blind study comparing the safety and efficacy of treatment with 0.1% tac-
rolimus ointment to that of a corticosteroid regimen in 80 patients. Recall antigen 
reactivity, transepidermal water loss and serum IgE concentrations were tested at 
baseline and after 6 and 12 months of treatment. Study III was a 10-year follow-up 
of respiratory symptoms in 50 patients participating in the 4-year, open tacrolimus 
ointment safety study. Data on bronchial hyper-responsiveness, respiratory symp-
toms, total serum IgE, and skin prick tests were collected at baseline and at the 
follow-up visit. Study IV was a 2-week pharmacokinetic study in 53 infants, 3 to 
24 months of age, with atopic dermatitis treated with 0.03% tacrolimus ointment 
once or twice daily. Full pharmacokinetic profiles for tacrolimus blood concentra-
tions were obtained at days 1 and 14. Study V investigated the efficacy and safety 
of 0.03% tacrolimus ointment in 50 infants treated for 2 years.   
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Long-term treatment with tacrolimus ointment showed good efficacy and did 
not result in any safety problems in adults, nor in infants with atopic dermati-
tis. Treatment with 0.1% tacrolimus ointment for one year enhanced recall an-
tigen reactivity in patients with atopic dermatitis almost to that of healthy con-
trols. Treatment with either 0.1% tacrolimus ointment or a corticosteroid regi-
men enhanced recall antigen reactivity after 12 months of treatment in a similar 
way. Transepidermal water loss, an indicator of skin barrier function, decreased 
at month 12 to approximately half its baseline value (P≤0.001) in both treatment 
groups. In patients with more than 60% improvement of the entire affected body 
surface area at month 12, serum IgE levels decreased from 666 at baseline to 584 
at month 12 (P=0.02). Patients in the 10-year, open follow-up study showed a 
decrease in affected body surface area from a baseline 19.0% to a 10-year 1.6% 
(P<0.0001), and those with bronchial hyper-responsiveness at baseline showed an 
increase (P=0.02) in the provocative dose of inhaled histamine producing a 15% 
decrease in FEV1, indicating less hyper-responsiveness. A decrease in respiratory 
symptoms occurred in patients with active symptoms at baseline. A good treat-
ment response (≥60% improvement in eczema) after one year of treatment with 
tacrolimus ointment predicted a good treatment response throughout the 10-year 
follow-up and a decrease in total serum IgE levels at the 10-year follow-up visit. 
The 2-week pharmacokinetic and the long-term safety study with 0.03% tacroli-
mus ointment showed good and continuous improvement of the eczema in the 
infants. Tacrolimus blood levels were throughout the study low and over time de-
creasing. Treatment was well tolerated.   
This thesis underlines the importance of effective long-term topical treatment of 
atopic dermatitis. When the active skin inflammation, with a Th2 cell dominance, 
decreases, cell-mediated immunity of the skin improves, and a secondary marker 
for Th2 cell reactivity, total serum IgE, decreases. Respiratory symptoms seem to 
improve when the eczema area decreases, but the lack of any control group in 
our study makes it difficult to evaluate the role of the initial 4-year intervention 
with tacrolimus ointment. All these effects can be attributed to improvement of 
skin barrier function, indicated by a decrease in transepidermal water loss. One 
potential method to prevent a progression from atopic dermatitis to asthma and 
allergic rhinitis may be avoidance of early sensitisation through the skin, so early 
treatment of atopic dermatitis in infants is crucial. Long-term treatment of atopic 
dermatitis with 0.03% tacrolimus ointment was effective and safe in infants over 
age 3 months. 
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1. atopic dermatitis
1.1 diagnosis and clinical features
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease which of-
ten appears in conjunction with other atopic diseases like atopic allergies, asthma, 
and allergic rhinitis. The diagnosis is clinical with no specific diagnostic clinical 
sign or laboratory test. In 1980, Hanifin and Rajka listed the main clinical features 
of AD, and these criteria are those most often referred to and most widely applied 
in clinical studies when setting the diagnosis of AD (Table 1). In epidemiological 
studies, the more simplified criteria of the UK Working Party are the most widely 
applied. Due do these criteria, a diagnosis of AD requires a pruritic skin disease 
plus three or more of the following: history of involvement of the flexural regions, 
history of asthma or hay fever, history of generally dry skin, onset at less than 
2 years of age, and visible flexural dermatitis (Williams et al 1994). Typical and 
mandatory for AD is the intense itch, an important cause of reduced quality of life 
in patients and their families. The majority of AD patients have increased levels of 
peripheral blood eosinophils and serum immunoglobulin E (IgE), and serum IgE 
levels show a high correlation with disease severity (Laske & Niggemann 2004, 
Clendenning et al 1973). Because some AD patients have normal serum IgE levels 
and no signs of sensitisation to allergens, AD can be divided into two forms: the 
extrinsic and the intrinsic. The extrinsic form affects 70 to 80% of patients, who 
show elevated serum IgE levels and sensitisation towards common allergens, while 
the intrinsic form affects 20 to 30%, who have normal serum IgE levels, no specific 
IgE to common allergens, and negative skin prick tests (Novak & Bieber 2003). The 
need for and validity of this type of classification has been debated (Williams & 
Flohr 2006), since IgE-mediated sensitisation may be only a transient factor. This 
is considered in a recently presented model which suggests that the natural history 
of AD has three consecutive phases: nonatopic, atopic, and autoallergic (Bieber 
2008). 
Skin lesions in the acute and sub-acute phases of AD are characterised by itch-
ing, erythematous papules, excoriations, and serous exudates. Chronic lesions 
are characterised by dryness, scaling, lichenification, papules, and excoriations. 
Histopathology in AD shows epidermal intercellular oedema, and infiltration of 
lymphocytes, macrophages, and dendritic cells around blood vessels. In licheni-
fied eczema, the epidermis is thickened and the upper layer hypertrophied. The 
normal-looking skin of AD patients is not normal but shows a subclinical inflam-
matory infiltrate (Mihm et al 1976) and impaired barrier function (Proksch et al 
2006). 
Localisation of the eczema varies with age. In infancy (under 1 year) lesions are 
typically on the cheeks, scalp, trunk, and extensor sides of the extremities. In child-
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hood (1-4 years) lesions can still be on the extensor sides of the extremities, but 
also in the flexures. In addition, face, neck, and hands can be affected. In ado-
lescents (4-16 years) the eczema is usually symmetrically distributed on the face, 
flexural areas, hands, feet, and sometimes back of the thighs. Beginning from pu-
berty and continuing into adulthood, lesions are typically on the face, upper body, 
flexures, and hands. Chronic hand eczema can be the main manifestation in many 
adults with AD. 
The common clinical term “atopic skin diathesis” includes atopic skin features such 
as dry skin, hyperlinear palms and soles, orbital darkening, winter feet, and nipple 
eczema (Wütrich & Schmid-Grendelmeier 2002). Persons with atopic skin diathe-
sis are at risk of developing occupational skin disease, and evidence supports the 
importance of recognizing this as part of an occupational skin disease-prevention 
strategy (Dickel et al 2003).
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Table 1. The Hanifin and Rajka criteria for diagnosis of AD (1980). 
Must have three or more basic features: 
1. Pruritus 
2. Typical morphology and distribution: 
Flexural lichenification or linearity in adults 
Facial or extensor involvement in infants and children 
3. Chronic or chronically relapsing dermatitis 
4. Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis) 
Plus three or more minor features: 
1. Xerosis 
2. Ichtyosis/ palmar hyperlinearity/ keratosis pilaris 
3. Immediate (type I) skin test reactivity 
4. Elevated serum IgE 
5. Early age of onset 
6. Tendancy toward repeated cutaneous infections (especially Staphylococcus aureus  
and Herpes simplex)/ impaired cell-mediated immunity 
7. Tendancy towards nonspecific hand or foot dermatitis 
8. Nipple eczema 
9. Cheilitis 
10. Recurrent conjunctivitis 
11. Dennie-Morgan infraorbital fold 
12. Keratoconus 
13. Anterior subcapsular cataracts 
14. Orbital darkening 
15. Facial pallor/ facial erythema 
16. Pityriasis alba 
17. Anterior neck folds 
18. Itch when sweating 
19. Intolerance to wool and lipid solvents 
20. Perifollicular accentuation 
21. Food intolerance 
22. Course influenced by environmental or emotional factors 
23. White dermographism/ delayed blanch 
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1.2 epidemiology
AD is a common disease with a lifetime prevalence of 10 to 20% in children and a 
point prevalence of 1 to 3% in adults (Schultz Larsen & Hanifin 2002). In Finnish 
young men, the prevalence of AD in 2003 was 1.2%, which, compared to its 
prevalence in 1966, is an over 6-fold increase (Latvala et al 2005). In a worldwide 
cross-sectional study known as the International Study of Asthma and Allergies in 
Childhood (ISAAC) the 12-month prevalence in 13- to 14-year-old children ranged 
from 0.9% in China to 15.6% in Finland, and to 21.1% in Bolivia (Odhiambo et 
al 2009). The ISAAC study also showed that the prevalence of AD during the last 
5 to 10 years is levelling off or decreasing in some countries with previously high 
prevalences, while many previously low-prevalence developing countries have ex-
perienced clear increases. No single environmental factor can explain the increase, 
and various risk factors, such as family size, hygiene, allergens, and changes in mi-
crobial environment are likely to be important in different countries (Williams et 
al 2008). In general, a two-to-three fold increase in AD occurred in industrialised 
countries during the last 30 years, with higher prevalences in urban than in ru-
ral regions. Agricultural regions, such as China, eastern Europe, and rural Africa 
show clearly lower prevalences (Taylor et al 1984). AD also seems to increase with 
higher socioeconomic status (Wolkewitz et al 2007). 
In 60% of the patients, eczema starts during the first year of life, and in 85% before 
age 5 (Kay et al 1994). In children with early (under age 2) manifestation of AD, 
43% were in complete remission after age 2. However, at age 7 nearly 20% had 
persistent symptoms and 38% intermittent symptoms (Illi et al 2004). In early ado-
lescence, about 60% of the children with AD will be symptom-free (Rystedt 1985), 
although up to half of them may have a relapse in adulthood (Lammintausta et al 
1991). Early-onset disease, severe early disease, concomitant asthma and allergic 
rhinitis, and a family history of AD may predict a more persistent course (Williams 
& Wüthrich 2000).
Parental and especially maternal AD is a major risk factor for AD. Another ma-
jor risk factor, which also could partly explain the increase in prevalence, is the 
western life-style, which generally leads to smaller families, better vaccination 
programs, and more frequent use of antibiotics (von Mutius 2000). The “hygiene 
hypothesis” suggests that infections are required during the first months of life in 
an infant to switch the intrauterine T helper (Th) type 2 cell dominance towards a 
non-atopic Th1 cell dominance; in atopic infants, this sequence is thought to fail 
(Strachan 1989). At present, some data do not support a clear inverse relationship 
between infections and risk for AD (Williams & Flohr 2006). Other risk factors 
may include maternal smoking and early respiratory syncytial virus infections 
(Lau et al 2000). 
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Studies of prevention of AD lack sufficient evidence for maternal dietary restric-
tions during pregnancy or lactation. For infants at high risk for atopic disease, 
exclusive breastfeeding for at least 4 months compared with feeding intact cow 
milk protein formula seems to reduce the cumulative incidence of AD (Greer et al 
2008). Prevention studies with probiotics show variable results, which at least in 
part can be explained by the use of differing probiotic bacteria and study sched-
ules. A study by Taylor and co-workers (2007) showed no reduction in AD risk in 
infants of 1 year of age who received probiotics for their first 6 months. In contrast, 
a large study in infants at high risk for allergy showed a reduced risk for AD by 
the age of 2 (Kukkonen et al 2007), but at 5 years of age a reduced risk appeared in 
only a very small subgroup, i.e., for IgE-associated eczema in cesarean-delivered 
children (Kuitunen et al 2009). 
Scientific rationale implies that simple means, such as consuming farm milk and 
spending time in nature, can endorse tolerance to environmental antigens and 
reduce risk of atopy. This has recently been summarised in the Finnish Allergy 
Programme 2008-2018 (von Hertzen et al 2009). 
  
1.3 genetics
AD results from a complex interplay between genetic and environmental factors. 
The genetic factors are strong, as can be seen in twin studies where the concord-
ance rate in monozygotic twins has been 72% compared with a rate of 23% in 
dizygotic twins (Larsen et al 1986, Schultz Larsen 1993). The presence of eczema-
specific genes is also supported by epidemiological studies which show that pa-
rental eczema constitutes a higher risk for eczema in the infant than does parental 
asthma or allergic rhinitis (Dold et al 1992). The disease risk of an infant seems 
more often to be related to maternal than paternal disease status (Dold et al 1992, 
Ruiz et al 1992, Diepgen & Blettner 1996). This could be due to genomic imprint-
ing, mitochondrial transmission, and gene-environment interactions involving 
the environment in the uterus or exposure to immunologic and nutritional factors 
of breast milk or both (Morar et al 2006). 
Genes of the epidermal differentiation complex are located on chromosome 1q21. 
The filaggrin gene on chromosome 1q21.3 encodes filaggrin, a key protein in epi-
dermal differentiation. Among European patients with AD, a nonfunctional mu-
tation of the filaggrin gene occurs in about 30% (Palmer et al 2006, Weidinger et 
al 2006, Marenholz et al 2006), whereas around 40% of all carriers of the filaggrin 
gene-null alleles will have no eczema (Henderson et al 2008). It therefore seems 
likely that filaggrin mutations cause a defective skin barrier, which in conjunc-
tion with additional genetic and environmental factors in many of the carriers, 
results in eczema. In European AD patients, six recurrent filaggrin gene mutations 
appear, plus several other family-specific mutations. The two most common are 
R501X and 2282del4 (Palmer et al 2006); AD patients with one of these are more 
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likely to have asthma, a persistent course of the disease, and atopic sensitisations 
(Marenholz et al 2006, Henderson et al 2008). Loss-of-function mutations of the 
gene from both parents is the cause of ichtyosis vulgaris, the most common inher-
ited disorder of keratinisation and one of the most common single-gene disorders 
in humans (Smith et al 2006). 
Genome-wide linkage studies have provided evidence of AD-related loci on chro-
mosome 3q21, containing the COL29A1 gene, which encodes a new epidermal 
collagen XXIX (Söderhäll et al 2007). Other AD-related loci occur on chromo-
some 17q25, which contains the keratin type I gene cluster genes, and on 20p and 
16q, which have been mapped by combining phenotypes, such as AD and asthma 
or AD and total serum IgE-level (Cookson et al 2001). The gene which encodes the 
β subunit of the high-affinity receptor for IgE (FcεRI) is located on chromosome 
11q12-13, found in a region with confirmed linkage to atopy.  
On chromosome 5q31-33, a cytokine gene cluster has been identified encoding 
mediators involved in the immune response, such as interleukin (IL)-4, IL-5, 
IL-12, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Morar et al 2006). This region also includes the SPINK5 gene, which encodes the 
lymphoepithelial kazal type-5 serine protease inhibitor (LEKTI), which inhibits 
two serine proteases: stratum corneum tryptic enzyme (kallikrein 5), and stra-
tum corneum chymotryptic enzyme (kallikrein 7) (Egelrud et al 2005). Patients 
with Netherton syndrome, a rare disease with severe atopic manifestations, carry 
mutations in the SPINK5 gene on both alleles (Sprecher et al 2001). They show 
marked barrier dysfunction, with altered desquamation and impaired keratinisa-
tion (Comel 1949). Several studies have linked mutations in the SPINK5 gene with 
AD, when maternally inherited (Walley et al 2001, Kato et al 2003, Nishio et al 
2003, Weidinger et al 2008).
1.4 skin barrier function
The epidermal barrier, found in the lower layers of the stratum corneum, serves 
as the first-line defense against invading pathogens and allergens. It is composed 
of differentiated keratinocytes, corneocytes, which are held together with cor-
neodesmosomes. Lipid lamellae, composed of ceramides, cholesterol, fatty acids, 
and cholesterol esters (Rawlings 2003), surround the corneocytes, providing a 
water-resistant layer which protects them from water loss (Lavker 1976). The cor-
neocytes contain natural moisturising factor, a breakdown product of filaggrin, 
which helps them to store water and subsequently swell. This in turn prevents 
gaps between them and makes the stratum corneum resistant to the penetration of 
allergens (Figure 1) (Cork et al 2009). Filaggrin is, together with other structural 
proteins, part of the cornified envelope which strengthens the corneocytes and 
helps lipids attach to them (Elias & Menon 1991). Filaggrin is of special impor-
tance, because it makes the corneocytes collapse into flattened discs with a large 
surface area (Steinert et al 1981). 
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Figure 1. Structural of the epidermal barrier. Corneocytes (green) are surrounded 
by lipid lamellae (yellow) and held together by corneodesmosomes (blue). Adapted 
from Cork et al 2008.
Transepidermal water loss (TEWL) can be measured by a special device (Pinnagoda 
et al 1990) and is widely used as a marker of skin barrier function. TEWL varies at 
different body sites, due to differences in skin thickness and in numbers of sweat 
glands. Patients with AD show dysfunction of the epidermal barrier, which can be 
seen as a two- to fivefold increase in TEWL, even in non-lesional skin. The degree 
of barrier impairment correlates with the phase of the disease – acute, subacute, 
and chronic – and with disease severity (Seidenari & Giusti 1995, Shahidullah et 
al 1969). 
The skin of AD patients, both those with and without the filaggrin mutation, 
shows decreased levels of filaggrin (Seguchi et al 1996). Patients with a filaggrin 
mutation show lower levels of filaggrin in acute lesional than in non-lesional skin. 
Overexpression of Th2 cytokines downregulates filaggrin expression during the 
differentiation process of the keratinocytes (Howell et al 2007), which explains the 
filaggrin deficiency seen in AD patients without the filaggrin mutation. Reductions 
in filaggrin levels lead to reduced levels of natural moisturising factor, which is 
important for skin hydration, has strong antimicrobial effects, and decreases skin 
colonisation of pathogenic bacteria (Cork et al 2009).
AD patients have significantly elevated pH of both lesional and non-lesional skin 
compared with that in normal controls (Eberlein-König et al 2000, Seidenari & 
Giusti 1995). A sustained increase in pH elevates the activity of degradatory pro-
teases and reduces the activity of the lipid synthesis enzymes. The activity of pro-
teases such as the stratum corneum tryptic (kallikrein 5) and chymotryptic (kal-
likrein 7) enzymes is strictly regulated by protease inhibitors (Suzuki et al 1994). 
LEKTI is a particularly important protease inhibitor and regulator of desquama-
tion, the inhibitory potential of which is reduced as the skin pH becomes more 
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acidic (Deraison et al 2007). Lack of kallikrein 5 inhibition by LEKTI in Netherton 
syndrome initiates thymic stromal lymphopoietin (TSLP) expression and triggers 
AD-like lesions, without any contribution from the environment or adaptive im-
mune system (Briot et al 2009). 
The outside-inside hypothesis suggests that barrier dysfunction can raise the activ-
ity of AD, by allowing antigens such as pollen and enterotoxins to penetrate the 
disrupted skin barrier. In contrast, the inside-outside hypothesis suggests that bar-
rier breakdown in AD is secondary to the inflammatory response to irritants and 
allergens (Cork et al 2009).     
1.5 pathogenesis
The initial cascade resulting in skin inflammation in AD is unknown. It may start 
with scratching, due to itching, irritation, or neuropeptides, leading to a release of 
pro-inflammatory cytokines from the keratinocytes, or may start with T cell reac-
tions towards allergens in the skin which have been able to penetrate the disrupted 
skin barrier (Bieber 2008). 
Both innate and adaptive immunity play roles in the pathogenesis of AD. The in-
nate (non-adaptive) immune responses are non-specific, whereas the adaptive im-
mune responses are highly specific for a particular pathogen. Innate responses do 
not alter during repeated exposure, whereas adaptive responses strengthen with 
each successive encounter with the target. T and B cells are central to all adaptive 
immune responses, since they exhibit the key features, specificity and memory, of 
adaptive immunity (Male & Roitt 1998).
Lesional skin in AD shows a dermal infiltrate of CD4+ and CD8+ T cells, in a ratio 
similar to that of peripheral blood. Some of the T cells in the immune system har-
bour the cutaneous lymphocyte antigen (CLA), which enables them to be quickly 
recruited to the skin if foreign antigens penetrate the skin barrier (Trautmann et 
al 2001). In the skin, naïve T cells, after antigen presentation by the dendritic cells, 
differentiate into Th1 and Th2 cells. 
  
It is generally accepted that AD reveals a disturbance of the Th1/ Th2-cell bal-
ance in the skin, with a shift towards overall Th2 dominance. The inflammation 
is biphasic, starting with an initial, acute Th2-predominant phase associated with 
increased secretion of IgE and cytokines such as IL-4, IL-5, and IL-13. This is fol-
lowed by a chronic phase in which Th0 and Th1 cells are dominant, with secretion 
of interferon (IFN)-gamma, IL-12, IL-5, and GM-CSF (Grewe et al 1995, Taha et 
al 1998). The switch from the acute to the chronic phase is initiated by increased 
levels of IL-12 and IL-18 produced by eosinophils or inflammatory dendritic epi-
dermal cells (IDECs), or both (Leung & Bieber 2003). Patients with AD commonly 
have elevated levels of eosinophils in serum and the skin. This is due to their in-
creased production in the bone marrow, and their recruitment and chemotaxis to 
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the site of inflammation by Th2 cytokines together with some chemokines such as 
eotaxin and monocyte chemoattractant protein 4. In addition, delayed apoptosis 
may also contribute to tissue eosinophilia (Simon et al 1998).
 
TSLP is an IL-7-like cytokine which in humans is expressed by keratinocytes in AD 
and by bronchial epithelial cells in asthmatic airways (Soumelis et al 2002, Ying et 
al 2005). TSLP is capable of activating CD11c+ myeloid dendritic cells to up-reg-
ulate co-stimulatory molecules, leading to the differentiation of CD4+ T cells into 
Th2 cells. It therefore plays a key role in the development of allergic diseases such 
as AD or asthma (Ziegler & Liu 2006, Leonard 2002, Liu 2006). TSLP can also act 
directly on T cells to enhance Th2 cytokine production (He et al 2008). 
A third Th cell subset, the Th17 cells, also seems to play an important role in AD 
by aggravation of the disease. The number of Th17 cells is increased in the pe-
ripheral blood and in acute lesional AD skin. These cells produce inflammatory 
cytokines such as IL-17A, IL-17F, IL-22, and IL-26. IL-17 stimulates keratinocytes 
to produce GM-CSF, tumour necrosis factor (TNF)-α, IL-8, CXCL10, and vascular 
endothelial growth factor (Koga et al 2008). Subtypes of Th cells and their possible 
roles in AD are presented in Figure 2.
Figure 2. Cytokine profiles of various types of T helper cells. Symbols: ↑=increase 
or ↓=decrease in activity shown in studies cited in the text, ?=only a few studies 
have suggested this, necessitating further verification.  
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Regulatory T cells may also play a role in AD in which the circulating amount is 
increased (Ou et al 2004). One study of lesional atopic skin showed that the in-
flammatory reaction of atopic skin was associated with an inadequate induction 
of tolerance due to the absence or defective function of human regulatory T cells 
(Verhagen et al 2006). 
Langerhans cells (LCs) and IDECs are different types of antigen-presenting den-
dritic cells (Wollenberg et al 1996), which in AD show increased expression of 
FcεRI on their surfaces, which is relevant for IgE binding (Bieber et al 1992, Klubal 
et al 1997, Wang et al 1992). The binding of specific IgE to the receptor leads to 
a 100- to 1000-fold increased antigen presentation to the Th1 and Th2 cells, and 
possibly also to regulatory T cells. LCs induce the production of some chemokines, 
but probably play a more important role in the induction and control of tolerance 
(Bieber 2007). In contrast, IDECs with activated FcεRIs may intensify the inflam-
matory immune reaction in patients with AD by producing high amounts of pro-
inflammatory cytokines and chemokines, and by contributing to the increased 
survival of monocytes and some antigen-presenting cells (Katoh et al 2000). The 
number of IDECs in the skin can be reduced by treatment with topical calcineurin 
inhibitors, but LCs are unaffected (Wollenberg et al 2001, Schuller et al 2004, 
Hoetzenecker et al 2005, Novak et al 2005). In contrast, topical corticosteroids 
induce apoptosis in LCs and impair their antigen-presenting capacity to T cells 
(Hoetzenecker et al 2004).
Patients with AD also show a variety of defects in their innate immune system that 
affect AD development and severity. Reduced function or migration into the skin 
of neutrophils, plasmacytoid dendritic, and natural killer cells occurs (Michaëlsson 
1973, Novak et al 2004, Wollenberg et al 2002, Katsuta et al 2006), as well as dys-
function of pattern-recognition receptors, such as Toll-like receptors (TLRs) 2 and 
9 (Hasannejad et al 2007, Novak et al 2007). TLRs are key molecules involved in 
microbial recognition by the immune system. Recent studies suggest that a muta-
tion in the TLR-2 modifies cytokine production and TLR expression in AD; as an 
end effect, both innate and adaptive responses in AD are modulated, which may 
be associated with enhanced susceptibility to skin infections with Staphylococcus 
aureus (Mrabet-Dahbi et al 2008, Niebuhr et al 2009).
AD patients also show decreased levels of antimicrobial peptides such as human 
beta-defensin-2 and -3, cathelicidin, and dermcidin. This reduced antimicrobial 
peptide expression is in part due to the inhibitory effects of the IL-4, -13, and 
-10 cytokines on the keratinocytes (Ong et al 2002, Nomura et al 2003, Howell 
et al 2006a). Antimicrobial peptides have antimicrobial properties and act as a 
link between innate and adaptive immune responses; for example, cathelicidins 
and some defensins have been chemoattractants for neutrophils, monocytes, and 
T cells (Yang et al 2001, Niyonsaba et al 2004). The defects in the innate immu-
nity of patients with AD amplify their susceptibility to skin infections and make 
these more difficult to manage (De Benedetto et al 2009). Modulins derived from 
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Staphylococcus epidermidis, a normal resident of the skin, seem to selectively in-
hibit the survival of pathogens, while maintaining the normal skin microbiome 
(Cogen et al 2010). Studies on skin microbiota will probably improve our under-
standing of the cutaneous microbiota and also shift paradigms in the interpreta-
tion of the roles microbes play in skin health and disease (Cogen et al 2008).
Itching is a dominant symptom of AD, and many studies have tried to identify 
the major pruritogen. Histamine was thought to be a major mediator of itch in 
AD, but the lack of effect of antihistamines contradicts this (Diepgen et al 2002). 
Mediators such as IL-2, GM-CSF, substance-P, acetylcholine, and prostaglandins 
induce itching (Ständer & Steinhoff 2002). IL-31, a T-cell-derived cytokine overex-
pressed in pruritic atopic compared with non-pruritic psoriatic skin inflammation 
(Sonkoly et al 2006), seems to be produced mainly by Th2 cells (Neis et al 2006). 
In a murine model, IL-31 antibody reduced scratching, but had no effect on skin 
lesions (Grimstad et al 2009). 
1.5.1 cell-mediated immunity
Cell-mediated immunity is a T cell-mediated defense mechanism against microbes 
that survive within phagocytes or that infect non-phagocytic cells. Activation of 
the phagocytes is dependent on Th1-produced interferon IFN-gamma, but Th17-
derived IL-17 also seems to play an important role in cell-mediated immunity 
(Nakae et al 2002). A delayed-type hypersensitivity (DTH) skin reaction is the 
result of phagocytic cell activation and inflammation and can serve to assess cell-
mediated immunity in vivo. DTH is commonly assessed by injecting an antigen 
such as tuberculin or tetanus intradermally; erythema and induration after 48 to 
72 hours indicate a positive reaction. The reaction is initiated when antigens are 
presented by antigen-presenting cells in the skin to sensitised T memory cells. The 
T cell activation leads to an influx of macrophages, monocytes, and lymphocytes 
at the site, which produce inflammatory cytokines such as TNF-alfa, IL-17A, and 
IFN-gamma. 
The lack of DTH to any recall antigens can indicate T cell immunodeficiency, 
and is termed anergy. Anergy is common in patients with sarcoidosis, rheuma-
tological diseases, and severe viral infections such as influenza or mononucleosis 
(Jyonouchi 2005). Many studies have shown an inverse association between tuber-
culin responses and atopy (Shirakawa et al 1997, Miyake et al 2008), while others 
have failed to do so (Grüber et al 2002). Impaired DTH reactions are evident in pa-
tients with active AD compared with healthy controls (Stenger et al 1983), as well 
as in apparently normal patients who have had multiple skin cancers (Czarnecki 
et al 1995). Systemic immunosuppressive treatment with ciclosporin or with pred-
nisolone and ciclosporin also inhibits DTH reactions (Ellis et al 1991, Rentenaar 
et al 2002).   
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1.5.2 immunoglobulin e
IgE synthesis is initiated by allergens which penetrate the epidermal barrier and 
are taken up via the FcεRIs by local antigen-presenting cells, which process and 
present them to Th cells. Th2 cells secrete cytokines that induce B cell proliferation 
and induce an allergen-specific IgE response. IgE production by B cells requires 
physical interaction with T cells, an interaction involving a number of surface ad-
hesion molecules, as well as with IL-4 and IL-13 produced by T cells, basophils, 
and mast cells. Mast cells and basophils play a key role by producing inflammatory 
mediators, but they can also directly regulate IgE production independently of T 
cells (Gauchat et al 1993).
The elevated IgE levels in the majority of the AD patients are probably due to many 
factors, such as the disrupted epidermal barrier which allows allergens to enter the 
skin and the Th2 dominance which provides a cytokine milieu suitable for IgE pro-
duction by B cells. Staphylococcal superantigens are able to stimulate IgE synthesis 
by peripheral blood mononuclear cells and this may contribute to elevated IgE 
levels in AD patients (Hofer et al 1995). In addition, the skin of AD patients shows 
higher expression of FcεRI than does the skin of healthy controls (Wollenberg et 
al 1995), and a correlation exists between FcεRI expression on skin dendritic cells 
and serum IgE levels (Kerschenlohr et al 2003).
The relevance of elevated IgE in patients with AD is not fully clarified, but many 
authors believe in a role for IgE in the pathogenesis of AD (Williams & Flohr 
2006); this is supported by a clear correlation between disease severity and IgE 
levels (Laske & Niggemann 2004). Results from low-dose anti-IgE therapy (oma-
lizumab) have been reported from an open study with 11 adult patients with gen-
eralised AD and high levels of total IgE. Only two patients responded with more 
than a 50% reduction in their eczema score. Total IgE (bound and free IgE) slightly 
increased during therapy, whereas free IgE remained nearly stable over the treat-
ment period (Belloni et al 2007). To date, no placebo-controlled studies have been 
published on anti-IgE therapy in the treatment of AD.
1.6 environmental factors
AD arises from an interaction between genetic and environmental factors. Factors 
such as bacteria and viruses, soap and detergents, stress, foods, and aeroallergens 
can trigger the inflammatory cascade and further break down the epidermal bar-
rier (Akdis et al 2006).
In most patients with active AD, S. aureus colonises the skin (Leyden et al 1974), 
in contrast to colonisation in less than 5% of healthy controls. The colonisation 
in AD is facilitated by impaired barrier function, reduced skin lipid content, high 
skin surface pH, increased adherence due to increased fibronectin and fibrinogen, 
and decreased production of antimicrobial peptides by the keratinocytes (Leung 
2008). In the majority of patients with AD, S. aureus secrets superantigens such 
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as enterotoxin A and B, and toxic shock syndrome toxin-1 (Nomura et al 1999). 
These play an important role in exacerbating AD and have induced T cell expres-
sion of the CLA skin homing receptor via stimulation of IL-12 production (Leung 
et al 1995). They also aggravate allergen-induced skin inflammation by activating 
infiltrating mononuclear cells and by inducing mast cell degranulation. AD se-
verity correlates with the presence of IgE against superantigens (Bunikowski et al 
1999, Nomura et al 1999). S. aureus also secretes proteinases able to break down 
corneodesmosomes (Miedzobrodzki et al 2002, Cork et al 2009). 
Patients with AD also suffer from viral skin infections such as Herpes simplex, 
Molluscum contagiosum, and Verruca vulgaris more often than do non-atopics. 
One reason for this can be the lower levels of interferon-gamma in the skin in 
AD patients than in healthy subjects, which can enable the overgrowth of viruses 
(Engler et al 2002). AD patients also show impaired skin recruitment of plasmacy-
toid dendritic cells, which respond to viral infections by producing large amounts 
of antiviral type I IFN-alfa and -beta (Wollenberg et al 2002), and decreased levels 
of the antiviral antimicrobial peptide cathelicidin in lesional skin and skin affected 
by eczema herpeticum (Ong et al 2002, Howell et al 2006b). These changes in the 
AD skin probably explain its predisposition to viral skin infections.  
Yeasts, especially Malassezia species, may play a role in AD pathogenesis, although 
study results are conflicting. Several studies show that patients with AD exclusive-
ly—particularly those with head and neck dermatitis—are sensitised to Malassezia 
(Faergemann 2002, Allam & Bieber 2003, Roll et al 2004, Bayrou et al 2005). In two 
double-blind, controlled studies, topical antifungal treatment added to 1% hydro-
cortisone cream has showed no benefit compared to that of hydrocortisone cream 
alone (Wong et al 2008, Broberg & Faergemann 1995). Systemic antifungal treat-
ment in clinical trials has reduced the severity of AD, but the explanation may be 
the non-specific anti-inflammatory effects of the drugs used (Brehler et al 2008). 
Increased washing and use of soaps and detergents has been associated with the 
increase in AD during recent decades. In the UK, sales of personal cleansing prod-
ucts rose over 80% between 1981 and 2001, while the population increase was 
less than 5% (Cork et al 2009). The use of soaps and detergents is one of the most 
common causes of irritant contact dermatitis of the hands and can cause AD flares 
(Meding & Swanbeck 1987). The irritant effects can partially be explained by the 
release of pro-inflammatory cytokines from corneocytes (Wood et al 1996, 1997). 
Soaps and detergents also increase skin pH (Mücke et al 1993), which further im-
pairs skin-barrier function in AD patients (White et al 1987).    
 
In children, the first manifestation of atopy is usually food allergy, but it is often 
transient and followed by allergy to inhalant aeroallergens (Heine et al 2008). Food 
allergens can induce skin rashes in up to 40% of children with moderate-to-severe 
AD (Eigenmann et al 1998). The skin symptoms include immediate reactions such 
as urticarial lesions, and early and late exacerbations of AD. Specific IgE, or positive 
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skin prick tests (SPTs) in infants and young children are most commonly found 
towards hen’s egg, cow’s milk, wheat, soy, and peanut (Lever et al 1998). Evidence 
for foods’ causing skin inflammation in AD is that T cells specific to food allergens 
have been cloned from skin lesions in AD patients (van Reijsen et al 1998). In 
addition, in a murine model, AD-like lesions were induced by oral sensitisation 
with food protein (Li et al 2001). An atopy patch test (APT) is an epicutaneous test 
originally developed to diagnose sensitisation to aeroallergens, but in the diagno-
sis of food allergy it is regarded as controversial by many groups, due to difficulties 
in interpretation of APTs and in standardising the technique (Heine et al 2008).
Inhalant aeroallergens seem to be more important than food allergy in older chil-
dren and adults in triggering AD (Werfel & Breuer 2004). Itchy skin lesions can 
develop after an intranasal or bronchial inhalation challenge with aeroallergens in 
sensitised patients with AD (Tupker et al 1996). Once entering the body, they initi-
ate a specific immune response leading to the generation and subsequent recruit-
ment of allergen-specific T cells into the skin, and thereby trigger AD. APTs with 
aeroallergens such as house dust mite, pollen, and cat danders on non-lesional skin 
can trigger eczema in 10 to 39% of AD patients (Darsow et al 2004). In contrast, in 
patients with only respiratory allergy and non-atopics, APTs are usually negative.  
 
About 25% of patients with AD have IgE autoantibodies against self-proteins from 
keratinocytes and endothelial cells, and serum levels of these correlate with disease 
severity (Altrichter et al 2008). This suggests a role for IgE autoantibodies in the 
pathophysiology and worsening of AD.    
Several other factors associated with worsening of AD are stress, seasonal changes, 
and wool or artificial fabrics (King & Wilson 1991, Varjonen et al 1992). 
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2. relationship of atopic dermatitis, atopic sensitisation, and at-
opic airway disease
Patients with AD frequently suffer from atopic airway disease, which includes al-
lergic rhinitis and asthma, and these diseases together form the atopic triad. Food 
allergies and AD in early childhood often precede asthma and allergic rhinitis at 
school age, and this subsequent development has been called the “atopic march” 
(Spergel & Paller 2003). This theory suggests that the defective skin barrier in AD 
leads to sensitisation towards allergens and skin inflammation, which subsequent-
ly leads to development of asthma and rhinitis. This is supported by Spergel and 
co-workers (1998) who showed that epicutaneous sensitisation with ovalbumin in 
a murine model can lead to systemic allergic responses and airway hyper-respon-
siveness after challenge with the same allergen. Other studies, though, do not sup-
port the theory of the atopic march, and suggest that a distinct disease phenotype 
may exist. This phenotype would exist as a co-expression of asthma and AD, char-
acterised in infancy by AD together with wheesing or a specific pattern of atopic 
sensitisation, and a more severe course of AD, resulting in significant impairment 
of lung function (Illi et al 2004, Williams & Flohr 2006).
2.1 atopic sensitisation
Atopic sensitisation, defined as the presence of specific IgE towards one or several 
allergens, is most commonly measured by either SPTs or specific IgE in sera. Atopic 
sensitisation to environmental allergens is common in infants and adults with AD 
with a prevalence of over 50% (de Benedictis et al 2009, Kyllönen et al 2006). Lack 
and co-workers (2003) showed an association between development of peanut al-
lergy with antigen exposure through disrupted atopic skin in early childhood. A 
murine study showed that mice with a defective skin barrier due to filaggrin defi-
ciency, in contrast to those with a normal skin barrier, could be sensitised through 
the skin with protein antigen (Oyoshi et al 2009). Allergic sensitisation towards 
grass, house dust mite, and cat dander, and sensitisation to multiple allergens is 
strongly associated with the filaggrin mutation in patients with AD (Henderson et 
al 2008). No genetic epidemiological studies on the association between food al-
lergy or anaphylaxis and filaggrin gene mutations have to date appeared (van den 
Oord & Sheikh 2009). 
2.2 allergic rhinitis
Allergic rhinitis is an inflammatory disease of the upper airways characterised by 
the symptoms of nasal congestion, rhinitis, sneesing, and nasal itching. Its preva-
lence in adults is estimated at between 10 and 30%, and in children up to 40% 
(Meltzer et al 2009). The pathophysiology is complex. In the early phase, mast 
cells and their degranulatory and secretory products play a key role. In the late 
phase, cytokines such as IL-5 promote infiltration of the mucosa by eosinophils, 
neutrophils, basophils, T-lymphocytes, and macrophages (Skoner 2001, Naclerio 
et al 1985). Th2 cells play an important role in promoting the allergic response by 
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releasing IL-3, IL-4, IL-5, and other cytokines that in turn promote IgE produc-
tion, eosinophil chemoattraction, and mast cell recruitment (Durham et al 1992). 
Allergic rhinitis is subdivided into intermittent and persistent, with persistent de-
fined as more than four consecutive days with symptoms per week (Bousquet et 
al 2008). 
The filaggrin gene defect in a patient elevates risk for allergic rhinitis (van den 
Oord & Sheikh 2009). Allergic rhinitis again elevates relative risk for adulthood 
asthma 3.5 fold, but rhinitis without atopy also elevates risk 2.7 fold (Shaaban et 
al 2008). A study by Akei and co-workers (2006) showed that initial epicutane-
ous sensitisation with an aeroallergen in a murine model led to nasal and airway 
inflammation and the development of BHR (bronchial hyper-responsiveness) to 
methacholine occurring after a single intranasal challenge with this same allergen. 
The authors conclude that the skin is an efficient site of sensitisation, and that their 
results support a connection between the nasal tract and the skin. 
2.3 asthma
Asthma is a chronic inflammatory disease of the airways characterised by a Th2-
type inflammation leading to reversible airway obstruction, BHR (exaggerated 
narrowing of the airways after inhalation of various stimuli), and tissue remodel-
ling. Asthma incidence has increased steadily during the last decades, with an espe-
cially high prevalence in westernised countries (Masoli et al 2004). The prevalence 
of physician-diagnosed asthma in Finnish schoolchildren and adults is 9% (von 
Hertzen et al 2009). The pathophysiology of asthmatic reactions involves most im-
portantly mast cells, eosinophils, and T cells, especially Th2 cells. Th17 cells, and 
mediators such as TSLP, IL-25, and IL-33 also probably play an important role in 
the pathogenesis (Barret & Austen 2009). Asthmatic patients have increased levels 
of IL-17A in the peripheral blood, sputum, and airways, levels correlated with de-
gree of BHR (Tesmer et al 2008, Barczyk et al 2003). Asthma is also associated with 
structural changes in the airways that include hyperplasia of the epithelium, with 
mucus metaplasia, and with increased airway smooth muscle mass and increased 
deposition of extracellular matrix proteins. Asthma classification involves its etiol-
ogy, phenotype, control, and severity (Gina Report 2009).
Patients with a nonfunctional mutation in the filaggrin gene and AD showed in-
creased risk for asthma, but AD patients without the filaggrin mutation did not 
(van den Oord & Sheikh 2009). These results provide evidence that, at least in 
some atopic patients, the filaggrin mutation may be an important predisposing 
factor for progression of allergic disease. In addition to a history of AD, wheesing 
in early childhood, allergic sensitisation to house-dust mites, and BHR all inde-
pendently elevate risk for asthma. The presence of more than one of these risk 
factors raises the risk even higher (Porsbjerg et al 2006).
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Patients with AD have, more than do healthy controls, BHR and eosinophilic air-
way inflammation (Kyllönen et al 2006). Patients with moderate-to-severe AD and 
BHR at baseline, when treated with topical tacrolimus for one year, showed a sig-
nificant decrease in BHR in the histamine challenge test, indicating that effective 
long-term treatment of AD may improve respiratory symptoms (Virtanen et al 
2007). This observation is supported by studies in two different murine models. 
The model of He and co-workers (2007) showed that epicutaneous, but not intra-
peritoneal, immunisation with ovalbumin raised serum IL-17 levels. Subsequent 
ovalbumin inhalations induced BHR, which was reversed by IL-17 blockade. In 
another murine model, the intrinsic skin barrier defect caused overexpression of 
TSLP in the skin and systemically, which, after allergen sensitisation of the lungs, 
led to BHR. This model required no epicutaneous sensitisation. Elimination of the 
TSLP signaling blocked the atopic march (Demehri et al 2009). 
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3. Topical treatment modalities in atopic dermatitis
As AD is a chronic disease, its treatment must be planned with a long-term per-
spective. Basic therapy in AD consists of avoidance of specific and unspecific pro-
vocation factors and skin hydration with emollients. Emollients act mainly by oc-
cluding water loss from the outer layers of the skin, by improving water binding of 
the skin, or by directly adding water to the dry outer layers of the skin. Emollients 
containing urea or vitamin B12 showed a benefit compared to the vehicle alone 
(Wilhelm & Scholermann 1998, Stücker et al 2004). Evidence indicates that some 
emollients can have a corticosteroid-sparing effect (Lucky et al 1997, Msika et al 
2008). Otherwise, evidence-based information on their efficacy is scarce, although 
they are widely used.
The cornerstone of AD treatment is topical anti-inflammatory therapy with topi-
cal corticosteroids and calcineurin inhibitors, although sometimes the disease 
cannot be controlled adequately with topical treatment, and secondary treat-
ments have to be introduced. These treatments include ultraviolet (UV) therapy 
and treatment with systemic immunosuppressive agents such as corticosteroids, 
ciclosporin, methotrexate, azathioprine, and mycophenolate mofetile. These di-
minish but do not abolish the need for topical corticosteroids. Of these treatments, 
only ciclosporin has been shown—in long-term studies of adults and children with 
severe AD—to be effective (>50% improvement) (Zonneveld et al 1996, Harper et 
al 2000). 
3.1 Topical corticosteroids
3.1.1 general properties and mechanism of action
Topical corticosteroids were introduced almost 60 years ago and still are the first-
line therapy for AD (Sulzberger & Witten 1952). The potency of new corticoster-
oids is usually determined by measurement of vasoconstriction, which correlates 
well with the clinical potency of well-known steroids (Cornell & Stoughton 1985). 
The local potency of a steroid depends not only upon its potency, but also on its 
ability to penetrate the epidermis barrier, and its molecular structure which deter-
mines its binding affinity to the steroid receptor and the interaction of the steroid-
receptor complex with target cell DNA. The vehicle also plays a role; generally cor-
ticosteroids in vehicles with high a percentage of lipids show higher potency than 
do those with a high percentage of water. Among various countries, this effect of 
vehicle on the potency of a corticosteroid preparation is only taken into account in 
the US classification (Nesbitt 2008). In Finland these are classified based on clini-
cal potency into mild (group I), moderate (group II), strong (group III), and very 
strong (group IV) corticosteroids. The strengths of topical corticosteroids include 
the extensive range of potencies and of formulations, like liniments, creams, and 
ointments. 
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Corticosteroid molecular mass is relatively small: For hydrocortisone acetate it is 
405 Dalton, and for betamethasone diproprionate, 505 Dalton (Buchwald 2008). 
Topical corticosteroids easily penetrate the epidermis and the upper dermis, with 
concentrations decreasing with increasing depth. After entering the cells, they 
bind to the glucocorticosteroid receptor in the cytoplasm, which mainly leads to 
up or/and down-regulation of gene expression. A variety of genes respond to the 
binding of the glucocorticosteroid receptor, i.e., those encoding structural proteins 
like collagen, enzymes like phospholipase A2, adhesion molecules, and cytokines 
(Lee et al 1991). 
3.1.2 efficacy
Compared to placebo in short-term studies, topical corticosteroids show a rapid 
and good treatment response. Treatment once daily seems to be as effective as 
twice-daily treatment (Bleehen et al 1995). Randomised controlled trials in AD 
have not found the addition of antimicrobials or antiseptics to a topical corticos-
teroid to be superior to the plain corticosteroid. This has been true for a combina-
tion of fucidic acid and betamethasone 17-valerate or 1% hydrocortisone acetate 
(Hjorth et al 1985, Ramsay et al 1996). 
Only a few double-blind, controlled, long-term studies on topical corticosteroid 
treatment are available, despite their widespread long-term use. Two vehicle-con-
trolled studies of 20 to 24 weeks’ duration showed that twice-weekly intermittent 
treatment with topical fluticasone propionate reduces risk for relapse in adult and 
paediatric AD patients (Hanifin et al 2002, Berth-Jones et al 2003). In addition 
two long-term (≥6 month) studies compared topical corticosteroids to tacrolimus 
ointment and pimecrolimus cream (Reitamo et al 2005, Luger et al 2004), studies 
reviewed in sections 3.2.4 and 3.3. 
3.1.3 safety
The safety of topical corticosteroids depends mainly on their clinical potency, du-
ration of treatment, patient age, treated body part and its surface area. 
The most important side-effect of topical corticosteroid treatment is skin atrophy, 
which clinically appears as striae, telangiectasias, and haematomas. Skin atrophy 
is mainly due to suppression of collagen synthesis (Oikarinen et al 1992), which is 
evident even in short-term studies measuring the aminoterminal propeptides of 
procollagen type I (PINP) and III (PIIINP). In a one-week study comparing cor-
ticosteroids of differing potency, hydrocortisone acetate reduced both PINP and 
PIIINP by 35%, and hydrocortisone butyrate PINP by 63% and PIIINP by 55% 
(Haapasaari et al 1995). Recovery of collagen synthesis is slow. Three days of treat-
ment with betamethasone-17-valerate in healthy men reduced collagen synthesis 
in the skin, and after a 2-week corticosteroid-free period, collagen synthesis had 
recovered to only about half that in non-treated skin (Haapasaari et al 1996).
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Topical corticosteroids also have direct negative effects on the epidermal skin 
barrier. Patients treated with topical corticosteroids have showed skin up to 70% 
thinner than that of untreated controls, a decrease in the amount of intercellular 
lipid lamellae, and increased TEWL (Sheu et al 1997). Topical corticosteroids also 
up-regulate expression of the gene for the stratum corneum chymotryptic enzyme 
known to impair barrier function (Yousef et al 2000). The rebound flare is prob-
ably due to skin barrier impairment which triggers an inflammatory response, 
when the anti-inflammatory treatment with topical corticosteroids ceases (Cork 
et al 2009).
Use of topical corticosteroids seems to lead to increased risk for lymphomas, es-
pecially skin lymphomas (odds ratio (OR) 1.46). This risk increases with longer 
duration of exposure and has been dependent on its potency with an OR of 1.80 
for high-potency topical corticosteroids (Arellano et al 2009). In an earlier study, 
severity of AD was associated with a 3-fold risk for lymphoma (Arellano et al 
2007). As most patients with AD would have been treated with corticosteroids, it 
is at present impossible to conclude definitely that corticosteroid treatment as such 
elevates risk for lymphoma. 
Long-term treatment with topical corticosteroids around the eyes can cause glau-
coma and cataract, and seems to be involved in the pathogenesis of perioral der-
matitis and acne (Hafeez 2003).
3.1.4 pharmacokinetics
In AD, the absorption of topical corticosteroids is increased in lesional skin, and 
even treatment with hydrocortisone acetate can lead to increased cortisol plasma 
levels. This means that in the acute phase of AD topical hydrocortisone treatment 
has both local and systemic effects. When the barrier function improves, absorp-
tion decreases (Turpeinen et al 1988). The absorption of hydrocortisone acetate in 
healthy skin depends on the treated body region. When compared to the volar side 
of the forearm, the absorption of steroids has been 42 times as high on scrotal skin, 
6 to 8 times as high on the face, and 5-fold lower on the palms (Maibach 1976). 
The eyelids, the scalp, the axilla, and the genital area show high penetration. Risk 
for skin atrophy increases with higher absorption; this should be considered when 
topical corticosteroids are prescribed.
3.2 Tacrolimus ointment
3.2.1 general properties and mechanism of action
Tacrolimus, also called FK506, was in 1984 isolated from the fungus-like bacteria 
Streptomyces tsukubaensis. It is chemically classified as a macrolide lactone with 
immunosuppressive activity 10 to 100 times as high as that of ciclosporin in sev-
eral in vitro systems. Tacrolimus was first studied as a systemic medication for 
prevention of graft rejection; later, topical formulations showed efficacy in inhi-
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bition of contact allergy reactions and in treatment of AD (Lauerma et al 1992, 
Nakagawa et al 1994). Absorption of topical tacrolimus compared to absorption 
of topical ciclosporin in vitro through human skin resulted in the greater absorp-
tion of tacrolimus (Lauerma et al 1997). In patients with AD, topical application of 
tacrolimus resulted in decreasing concentrations of the compound with increasing 
skin depth. Tacrolimus was primarily partitioned in the skin, topical application 
leading to minimal systemic absorption (Undre et al 2009). 
The tacrolimus molecule has a large molecular mass, 824 Dalton, and is highly li-
pophilic (Figure 3). The ointment is indicated for treatment of moderate-to-severe 
AD, with a 0.1% concentration labelled for adult patients and the 0.03% concentra-
tion for children at least 2 years old.    
 
Figure 3. The tacrolimus molecule
Tacrolimus binds in the T cells to a cellular receptor, the FK-binding protein 
(FKBP; macrophilin-12). The tacrolimus-FKBP complex then binds to and inhib-
its calcineurin, which in turn leads to inhibition of dephosphorylation and nuclear 
translocation of a cytosolic transcription factor, the nuclear factor of activated T 
cell protein. This cascade blocks the production of cytokines such as IL-2, IL-4, 
IL-8, TNF-alfa, IFN-gamma, and GM-CSF, and this leads to inhibition of Th1 and 
Th2 cell activation (Luger et al 2008). Tacrolimus also inhibits cytokine production 
from eosinophils, mast cells, and basophils, and inhibits the release of mast cell me-
diators such as histamine (Alomar et al 2004, Hatfield et al 1992). Treatment of AD 
with tacrolimus ointment reduces expression of FcεRI on both Langerhans cells 
and IDECs, and down-regulates the IDEC population (Wollenberg et al 2001).    
3.2.2 efficacy in short-term studies
The first placebo-controlled clinical trial studied tacrolimus ointment in three con-
centrations (0.03%, 0.1%, 0.3%) for 3 weeks in 13- to 60-year old patients with AD. 
Tacrolimus ointment in all concentrations showed superior efficacy to its vehicle 
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from the third treatment day onwards to the end of the study. The only adverse 
event was a burning sensation in treated areas (Ruzicka et al 1997). These find-
ings were confirmed later in both adults and children with moderate-to-severe AD 
(Reitamo et al 2002a). 
Tacrolimus ointment has been compared to pimecrolimus cream in children and 
adults with AD in three investigator-blinded, randomised, comparative 6-week 
studies. In the meta-analysis of these studies, tacrolimus ointment was more effec-
tive, with an onset of action faster than for pimecrolimus cream, and their safety 
profiles were similar (Paller et al 2005).
3.2.3 efficacy in long-term studies
The published long-term studies with tacrolimus ointment are summarised in 
Table 2. Most open-label long-term clinical studies ranging from 6 months to 4 
years have used 0.03% or 0.1% tacrolimus ointment twice daily until clearance, 
and in the case of any new lesions twice daily treatment restarted. These studies 
have shown sustained, excellent improvement of the eczema, without any signs of 
tachyphylaxis (Kang et al 2001, Reitamo et al 2000, 2007, 2008, Remitz et al 2007). 
Two long-term studies suggest that need for tacrolimus ointment decreases over 
time when the skin heals (Reitamo et al 2000, 2008). 
Recently, intermittent (proactive) tacrolimus ointment treatment twice weekly for 
flare prevention, has been studied. During the initial period it was applied twice 
daily to all affected areas up to an Investigator Global Assessment (IGA) score of 
2 or less. Patients then entered the disease-control period and were randomised to 
either tacrolimus ointment or vehicle twice weekly for 12 months. Studies in both 
children and adults showed that intermittent treatment with tacrolimus ointment 
(0.03% in children and 0.1% in adults) significantly reduced the number of dis-
ease exacerbations requiring treatment compared to vehicle treatment (Thaçi et al 
2008, Wollenberg et al 2008).
Clinical trials in children aged 2 to 15 with moderate and severe AD have shown 
significant improvement with both 0.03% and 0.1% tacrolimus ointment (Kang 
et al 2001, Remitz et al 2007). Infants under 2 (n=12) have been studied once, 
retrospectively. Improvement in the AD resulted in low tacrolimus blood levels of 
less than 1.5 ng/mL, measured at a minimum of 1 month after treatment initiation 
(Patel et al 2003).   
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3.2.4 clinical studies comparing topical corticosteroids and tacrolimus oint-
ment
Tacrolimus ointment has been compared to several topical corticosteroids in 
short-term studies. Tacrolimus 0.1% ointment was as effective as hydrocortisone 
butyrate 0.1% ointment, but tacrolimus 0.03% ointment was less effective in adult 
patients with moderate-to-severe AD (Reitamo et al 2002b). In 2- to 15-year-old 
children, both 0.1% and 0.03% doses were more effective than was hydrocortisone 
acetate ointment (Reitamo et al 2002c). 
Tacrolimus ointment has also been compared to 0.005% fluticasone pivalate oint-
ment. In treatment of facial eczema, 0.1% tacrolimus was superior to fluticasone 
in adults in a 3-week study (Doss et al 2009a), while 0.03% tacrolimus showed 
similar efficacy as did fluticasone for children in a 6-week study (Doss et al 2009b). 
Another study with 2- to 15-year-old children compared the efficacy of 0.1% 
methylprednisolone aceponate ointment once daily to that of 0.03% tacrolimus 
ointment twice daily for 3 weeks in the treatment of a severe to very severe flare 
of AD. The methylprednisolone aceponate showed better efficacy for the Eczema 
Area and Severity Index (EASI), sleep, and itch, and the IGA was similar for both 
treatments (Bieber et al 2007).   
       
In one 6-month, double-blind study, tacrolimus 0.1% ointment was compared to 
a corticosteroid regimen (1% hydrocortisone acetate for head and neck, and 0.1% 
hydrocortisone butyrate for trunk and limbs) in 972 adult patients with moderate-
to-severe AD. In that study, tacrolimus ointment showed efficacy superior to that 
of the corticosteroid regimen throughout (Reitamo et al 2005).
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The published long-term studies with tacrolimus ointment are summarised in Table 2. Most open-
label long-term clinical studies ranging from 6 months to 4 years have used 0.03% or 0.1% 
tacrolimus ointment twice daily until clearance, and in the case of any new lesions twice daily 
treatment restarted. These studies have shown sustained, excellent improvement of the eczema, 
without any signs of tachyphylaxis (Kang et al 2001, Reitamo et al 2000, 2007, 2008, Remitz et al 
2007). Two long-term studies suggest that need for tacrolimus ointment decreases over time when 
the skin heals (Reitamo et al 2000, 2008).  
Recently, intermittent (proactive) tacrolimus ointment treatment twice weekly for flare prevention, 
has been studied. During the initial period it was applied twice daily to all affected areas up to an 
Investigator Global Assessment (IGA) score of 2 or less. Patients then entered the disease-control 
period and were randomised to either tacrolimus ointment or vehicle twice weekly for 12 months. 
Studies in both children and adults showed that intermittent treatment with tacrolimus ointment 
(0.03% in children and 0.1% in adults) significantly reduced the number of disease exacerbations 
requiring treatment compared to vehicle treatment (Thaçi et al 2008, Wollenberg et al 2008). 
Clinical trials in children aged 2 to 15 with moderate and severe AD have shown significant 
improvement with both 0.03% and 0.1% tacrolimus ointment (Kang et al 2001, Remitz et al 2007). 
Infants under 2 (n=12) have been studied once, retrospectively. Improvement in the AD resulted in 
low tacrolimus blood levels of less than 1.5 ng/mL, measured at a minimum of 1 month after 
treatment initiation (Patel et al 2003).    
 
Table 2. Long-term studies (!6 months) with tacrolimus ointment     




(years) Treatment  
Duration 
(months) 
Reitamo et al. 2000 Open, non-comparative 316 !18 0.1%  tac 6-12 
Kang et al 2001 Open, non-comparative 255 2-15 0.1% tac 12 
Hanifin et al 2005 Open, non-comparative 799 !2 0.1% tac up to 40 
Reitamo et al 2007 Open, non-comparative 672 !18 0.1% tac 24 
Remitz et al 2007 Open, non-comparative 466 2-15 0.03% or 0.1% tac 29 
Reitamo et al 2008 Open, non-comparative 782 !2 0.1% tac 48 
Wollenberg et al 2008 Double-blind, intermittent 257 !18 0.1% tac vs vehicle 12 
Thaçi et al 2008 Double-blind, intermittent 267 2-15 0.03% tac vs vehicle 12 
Breneman et al 2008 Double-blind, intermittent 197 !2 0.03% or 0.1% tac vs vehicle  10 
Paller et al 2008 Double-blind, intermittent 105 2-15 0.03% tac vs vehicle 10 
Reitamo et al 2005 Double-blind 972 !18 0.1% tac vs steroid 6 
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3.2.5 safety
The safety of tacrolimus ointment has been examined in several short- and long-
term clinical studies in both children and adults. A recent review of the long-term 
safety of tacrolimus ointment revealed no long-term safety problems (Remitz & 
Reitamo 2009). The most common application-site adverse event is a burning 
sensation reported in about 60% of the adult and 40% of the paediatric patients 
(Ruzicka et al 1997, Reitamo et al 2002b). This sensation is usually transient, and 
when treatment is continued, its incidence decreases over time (Reitamo et al 
2000). Other common application-site adverse events are pruritus, skin tingling, 
hyperaesthesia, and folliculitis. Alcohol intolerance, which is characterised by facial 
flushing after intake of even a small amount of alcohol, is an adverse event specific 
for treatment with tacrolimus ointment (Reitamo et al 2000, 2005). Acetylsalicylic 
acid taken orally one hour before tacrolimus treatment seems to reduce or inhibit 
symptoms both of this alcohol reaction and of the local burning sensation and 
pruritus when treatment is initiated (Mandelin et al, unpublished observation).
In the 6-month, double-blind study, Herpes simplex skin infections showed a high-
er incidence during the first months in patients treated with tacrolimus ointment 
vs patients treated with the corticosteroid regimen. Between these groups after 
6 months of treatment, incidence was comparable (1.3% in tacrolimus vs 1.0% 
in steroid-treated patients). No increase in bacterial skin infections was evident 
in tacrolimus-treated patients (Reitamo et al 2005). In contrast, one uncontrolled 
1-year tacrolimus study showed decreased colonisation with S. aureus when skin 
lesions healed (Remitz et al 2001). 
 
Initially, one short-term, double-blind study showed that topical tacrolimus does 
not reduce collagen synthesis (Reitamo et al 1998). A 1-year study with intermit-
tent tacrolimus monotherapy in patients with AD showed an increase in the syn-
thesis of PINP and PIIINP in the skin, accompanied by an increase in skin thick-
ness measured by an ultra-sound device (Kyllönen et al 2004). 
Tacrolimus ointment does not elevate ocular pressure (Remitz et al 2010), and to 
date there exist no reports of cataract after topical tacrolimus treatment.
Risk for skin cancer is related to systemic immunosuppression and UV radiation. 
That tacrolimus ointment is a topical immunomodulating agent has inspired inter-
est in study of any skin cancer risk. A follow-up study with a maximum observa-
tion period of up to 4 years did not report an increased risk for non-melanoma 
skin cancer in AD patients treated with tacrolimus ointment (Naylor et al 2005). 
Topical tacrolimus associated with non-melanoma skin cancer in one murine study 
(Niwa et al 2003). In contrast, several animal studies suggest a decreased risk for 
skin cancer with tacrolimus treatment, which inhibited development of phorbol 
ester-induced skin tumours (Jiang et al 1993), and caused activation of the trans-
forming growth factor (TGF)-β-1-receptor, playing an important role in wound 
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healing and tumour formation (Yao et al 2000). Tacrolimus and pimecrolimus 
were both able to reduce UVB-induced thymidin-dimer formation, and thus pre-
vent DNA damage (Tran et al 2005), and neither accelerated photocarcinogenesis 
nor induced any dermal carcinogenesis in hairless mice (Lerche et al 2008, 2009).
 
In a large study including almost 300 000 patients the risk for lymphomas in pa-
tients treated with topical calcineurin inhibitors was not increased (Arellano et 
al 2007). The only work suggesting increased risk for lymphoma has been one on 
T cell lymphoma which showed an increased risk at a median time of 1.4 years 
from tacrolimus exposure to T cell lymphoma. The mean cumulative amount of 
tacrolimus prescribed did not significantly differ in patients with lymphoma com-
pared to patients without and was less than 100 grams for 0.1% tacrolimus oint-
ment. No risk for any other cancer was observable. Unfortunately, this study did 
not address corticosteroid use by these patients (Hui et al 2009). These findings 
contradict those of two 4-year safety studies of tacrolimus, showing no increased 
risk for any cancer (Hanifin et al 2005, Reitamo et al 2008).
3.2.6 pharmacokinetics
All pharmacokinetic studies available to date have indicated that in long-term 
treatment of AD systemic absorption of topically applied tacrolimus is minimal. 
When 12 clinical studies with a total of 2015 adult and paediatric patients treat-
ed with 0.03 to 0.3% tacrolimus ointment were analysed in combination, results 
showed low or minimal systemic exposure. The treatment period ranged from 1 
week to 12 months, with a total treated area of up to 100%. The maximum tac-
rolimus concentration was below 0.5 ng/mL for 60.5% of patients, 0.5-1 ng/mL for 
20.6%, 1-<2 ng/mL for 10.9%, 2-<5 ng/mL for 6.7%, and over 5 ng/mL for 1.3%. In 
any patients with any measurable tacrolimus blood concentration, it was transient, 
with decreasing concentrations when the skin healed (Reitamo 2002). 
The pharmacokinetic profile in children over age 2 has been similar to that in 
adults. One pharmacokinetic study in children aged 6 to 12 years treated with 0.1% 
tacrolimus ointment showed minimal systemic exposure, with 92% of the blood 
samples containing tacrolimus concentrations below 1 ng/mL. Concentrations 
tended to increase proportionally as the size of the BSA treated increased; ab-
sorption decreased with time as the skin lesions healed (Harper et al 2005). A 
study involving children aged 2 to 5 years showed similar pharmacokinetic results 
(Krueger et al 2007).  
Daily trough tacrolimus levels of 5-20 ng/mL are recommended in transplant re-
cipients to avoid allograft rejection. Notably, in patients with Netherton syndrome, 
a disease with marked skin-barrier impairment which in infants can be mistaken 
for AD, topical tacrolimus treatment has showed high systemic tacrolimus con-
centrations comparable to those after oral treatment (Allen et al 2001), making 
topical tacrolimus treatment not recommended for Netherton syndrome.           
reVieW of THe liTeraTure
34
3.3 pimecrolimus cream
Pimecrolimus (ASM 981) is a semisynthetic derivative of ascomycin and differs 
from tacrolimus at a single site with an ethyl group instead of the propenyl side-
chain residue. Its mechanism of action is similar to that of tacrolimus, with an 
initial binding to the FKBP (macrophilin-12), which is about three times as weak 
in vitro as is tacrolimus (Bochelen et al 1999). Its clinical efficacy also seems to 
be inferior to that of tacrolimus (Paller et al 2005, Abramovits et al 2008). Topical 
pimecrolimus is indicated for treatment of mild-to-moderate AD, in adults and 
children of at least 2 years of age. 
A 3-week proof-of-concept study of 1% pimecrolimus cream in adults with mod-
erate AD showed the superiority of twice-daily treatment to treatment once daily 
and to vehicle (Van Leent et al 1998). A dose-finding 3-week study in adults with 
AD compared increasing concentrations of pimecrolimus cream (0.05%, 0.2%, 
0.6%, and 1%) to betamethasone 17-valerate cream. The highest concentration 
was the most effective for pimecrolimus with a median EASI decrease of 47%, 
while betamethasone 17-valerate cream was more effective with a median de-
crease of 78% compared to baseline (Luger et al 2001). Long-term clinical studies 
in infants, children, and adults have focused on pimecrolimus as a steroid-sparing 
agent and showed that it, compared to the vehicle, reduces the number of flares 
needing treatment with topical corticosteroids (Kapp et al 2002, Wahn et al 2002, 
Meurer et al 2002). One long-term, double-blind controlled study has compared 
the efficacy of 1% pimecrolimus cream to a corticosteroid regimen (hydrocorti-
sone acetate cream for head and neck and 0.1% triamcinolone acetonide cream 
for trunk and limbs). Efficacy was better in the corticosteroid group, and only 42% 
of pimecrolimus-treated patients could be maintained without corticosteroids for 
one year (Luger et al 2004). A meta-analysis which included children aged 2 to 17 
from eight randomised controlled trials indicated that patients treated with both 
0.03% and 0.1% tacrolimus ointment showed a significantly higher response rate 
than did those treated with 1% pimecrolimus or 1% hydrocortisone acetate (Yan 
et al 2008). 
Pimecrolimus has been studied in infants with AD under age 2 and showed supe-
rior efficacy compared to placebo, and had a good safety profile in one 6-month 
study (Ho et al 2003). In a 3-week study in infants with AD treated with 1% pime-
crolimus cream twice daily, pimecrolimus blood concentrations were minimal 
(Staab et al 2005). 
The safety profile of 1% pimecrolimus cream is very good; pharmacokinetic stud-
ies show low systemic exposure (Luger et al 2008). Local adverse events, like skin 
burning, seem to occur at a similar frequency for topical pimecrolimus and for 
tacrolimus treatment (Abramovits et al 2008).
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aims of THe sTudY
The main aim of this study was to evaluate the effects of long-term topical tac-
rolimus treatment on AD skin and atopic respiratory disease. 
The specific aims of this study were to determine:
the effect of long-term tacrolimus ointment treatment in patients with AD 
on their cell-mediated immunity.
 
the long-term efficacy, safety, and effects on the Th1/Th2 balance in pa-
tients with AD treated with tacrolimus ointment or with a corticosteroid 
regimen.
the 10-year outcome of eczema, respiratory symptoms, and serum IgE le-
vels in AD patients initially treated long-term with tacrolimus ointment.
the pharmacokinetics and long-term safety and efficacy of tacrolimus oint-
ment in infants under age 2 with AD.






suBJecTs and meTHods 
1.  patients
Patients in Studies I to III were recruited from the outpatient clinic of the 
Department of Dermatology, Helsinki University Central Hospital. Patients in-
cluded in Study I participated in a 4-year open tacrolimus safety study, and all 
patients recruited for the 10-year follow-up had also participated in the 4-year 
study. Thus patients in Studies I and III in part overlapped, but were at baseline in 
Study I aged ≥16 years and in Study III aged ≥13 years. Patients in Study II were 
aged ≥18. Study IV was a paediatric, multi-centre study with patient recruitment 
in Finland, Ireland, the UK, Latvia, and Canada. Patients in Finland were all re-
cruited at the Children’s Department of the Skin and Allergy Hospital, Helsinki 
University Central Hospital, and were aged between 3 and 24 months. Study V was 
a follow-up and included only patients who participated in Study IV. (Table 3).




Patients in Studies I to III were recruited from the outpatient clinic of the Department of 
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!18. Study IV was a paediatric, multi-centre study with patient recruitment in Finland, Ireland, the 
UK, Latvia, and Canada. Patients in Finland were all recruited at the Children’s Department of the 
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Table 3. Baseline characteristics and reasons for withdrawal.  





Study duration Reasons for withdrawal (n) 
I 48 26.1 17/31 12 months Lack of efficacy (1), unavailable for testing at 
month 12 (2) 
II:      
Tacrolimus 
ointment 




40 29.3 10/30 12 months Lack of efficacy (4), prohibited therapy (2), 
non-compliance (1), pregnancy (1), lost to 
follow-up (1) 
III 50 33.0 16/34 10-year follow-
up 
Not applicable 
IV 53 1.2 32/21 28 days Withdrawal of consent (1), other (2) 
V 50 1.2 31/19 48 months Withdrawal of consent (3), adverse event (2), 
lost to follow-up (2), non-compliance (1), lack 




All studies required the patients to have an AD diagnosis according to the Hanifin and Rajka (1980) 
criteria, and an affected area greater than or equal to 5% of total BSA at baseline. Studies I to III 
also required patients to have moderate-to-severe AD at baseline based on the grading system of 
Rajka and Langeland (1989), whereas patients in Study IV had to need AD treatment with mid-
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1.1 inclusion and exclusion criteria
All studies required the patients to have an AD diagnosis according to the Hanifin 
and Rajka (1980) criteria, and an affected area greater than or equal to 5% of to-
tal BSA at baseline. Studies I to III also required patients to have moderate-to-
severe AD at baseline based on the grading system of Rajka and Langeland (1989), 
whereas patients in Study IV had to need AD treatment with mid-potency topi-
cal corticosteroids. Inclusion criteria for Study V were participation in Study IV 
and having benefitted from treatment with 0.03% tacrolimus ointment, according 
to the investigator. Wash-out criteria before study enrollment are summarised in 
Table 4. Exclusion criteria are listed in Table 5.
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potency topical corticosteroids. Inclusion criteria for Study V were participation in Study IV and 
having benefitted from treatment with 0.03% tacrolimus ointment, according to the investigator. 
Wash-out criteria before study enrollment are summarised in Table 4. Exclusion criteria are listed in 
Table 5. 
 
Table 4. Wash-out criteria before study enrollment.       
Therapy Study I, III Study II Study IV Study V 
All medicated topical treatment, 
including corticosteroids 5 days 3 days 3 days 3 days 
Antimicrobials n.r. 5 days n.r. n.r. 
Systemic antihistamines: n.r. 5 days n.r. n.r. 
terfenadine 5 days 5 days n.r. n.r. 
astemizole 6 weeks 5 days n.r. n.r. 
intranasal and/or inhaled 
corticosteroids (>1 mg/day) 2 weeks 1 week n.r. n.r. 
Systemic corticosteroids 4 weeks 4 weeks 4 weeks 5 days (for treat-
ment of AD only) 
Systemic non-steroidal immuno-
suppressants (e.g. CSA, MTX) 4 weeks 2 weeks 3 days 2 weeks 
Other investigational drugs 4 weeks 4 weeks 4 weeks 4 weeks 
UV therapy 6 weeks 6 weeks 6 weeks 6 weeks 
Doxepin n.r. 3 days n.r. n.r. 
Non-live attenuated vaccinations n.r. n.r. 2 weeks n.r. 
Live attenuated vaccinations n.r. n.r. 4 weeks n.r. 
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Table 5. Exclusion criteria for studies indicated by their Roman numerals (I-V) 
Patient has/ Patient is: 
• an infection requiring treatment (I-III, V) 
• a systemic disease, including cancer or history of cancer or AIDS, which would 
contraindicate the use of tacrolimus ointment (I-V) 
• a chronic disease that is unstable or uncontrolled (IV) 
• diabetes mellitus which is either unstable, poorly controlled, or insulin dependent (I, III) 
• clinically significant impairment of renal or hepatic function (I-V) 
• clinically infected AD (I-V) 
• a history of eczema herpeticum (I, III) 
• a skin disorder, other than AD, requiring treatment (I-V) 
• any lesion, other than scalp or mucosa, which in the opinion of the investigator cannot be 
treated with study ointment (II, IV, V) 
• extensive scarring or pigmented lesions in the treatment area, which would interfere with 
rating of efficacy parameters (II) 
• known allergic response to macrolides or any excipient of the ointment (I-V) 
• a history of more than two courses of systemic corticosteroid treatment (IV) 
• any form of substance abuse, psychiatric disorder or condition which, in the opinion of the 
investigator, may invalidate the communication with the investigator (I-III) 
• received a vaccination in the last 14 days (28 days in the case of a live attenuated 
vaccination) (IV) 
• previously been treated with tacrolimus or has participated in any Fujisawa (now Astellas) 
sponsored trial and received at least one dose of tacrolimus (II) 
• known to be HIV positive (I-V) 
• pregnant or breast feeding (I-III) 




During the 4-year open 0.1% tacrolimus study, within which Study I and part of Study III were 
conducted, the following concomitant medications were prohibited: UV therapy, non-steroidal 
immunosuppressants, medicated topical agents, astemizole, terfenadine, more than 1 mg/day of 
intranasal and/or inhaled corticosteroids, or other investigational drugs. The use of systemic and 
topical corticosteroids was prohibited during the first 6 months, whereafter, rescue therapy for 
worsening of AD was allowed for a maximum of 2 weeks in every 3 months. Use of non-steroidal 
anti-inflammatories was permitted for use up to 2 weeks in any 3 months. Emollients were 
permitted 2 hours prior to or after the use of the study ointment. 
Study II included all these restrictions and permissions, but in addition all systemic antihistamines, 




During the 4-year open 0.1% tacrolimus study, within which Study I and part of 
Study III were conducted, the following concomitant medications were prohib-
ited: UV therapy, non-steroidal immunosuppressants, medicated topical agents, 
astemizole, terfenadine, more than 1 mg/day of intranasal and/or inhaled corti-
costeroids, or other investigational drugs. The use of systemic and topical corti-
costeroids was prohibited during the first 6 months, whereafter, rescue therapy for 
worsening of AD was allowed for a maximum of 2 weeks in every 3 months. Use 
of non-steroidal anti-inflammatories was permitted for use up to 2 weeks in any 
3 months. Emollients were permitted 2 hours prior to or after the use of the study 
ointment.
Study II included all these restrictions and permissions, but in addition all systemic 
antihistamines, antimicrobials influencing efficacy assessments, and sleeping pills 
and tranquilisers were prohibited. Systemic and topical corticosteroids were not 
allowed for the treatment of AD, and for other indications only for a maximum of 
2 weeks in any 3 months. 
Prohibited therapies in Study IV included UV therapy, non-steroidal immunosup-
pressants, topical and systemic corticosteroids, other investigational drugs, and 
vaccinations. The use of inhaled and nasal corticosteroids was restricted to <1 mg/
day. Study V included the same restrictions, but in addition, other topical immu-
nomodulators were prohibited. Treatment with topical corticosteroids for up to 
2 weeks in any 3-month period and vaccinations were permitted. In the case of 
vaccinations, topical tacrolimus treatment had to be discontinued for 5 to 7 weeks, 
and during this period treatment with topical corticosteroids was allowed.   
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2. study designs and protocols
The study protocols for Studies I to V were approved by the local ethics committee 
at Helsinki University Central Hospital. All patients or their parents in Studies IV 
and V, gave written informed consent before the start of the study. The use of study 
medication, either tacrolimus ointment or the corticosteroid regimen (in Study II) 
was approved by the National Agency for Medicines (Lääkelaitos).
Studies I and III were open, single-centre studies conducted in patients who were 
participating or had participated in a long-term multi-centre safety study of 0.1% 
tacrolimus ointment. Study II was a one-year double-blind randomised controlled 
study, where patients were treated with either 0.1% tacrolimus ointment or a corti-
costeroid regimen. Some of the efficacy and safety data from the first 6 months of 
the study were included in a large multi-centre study (Reitamo et al 2005). Study 
IV was a randomised double-blind pharmacokinetic multi-centre study, in which 
patients were treated with 0.03% tacrolimus ointment either once or twice daily. 
Following enrollment, patients were allocated to three different groups depending 
on the affected body surface area (BSA): Group 1, 5 to 20%, Group 2, >20 to 40%, 
and Group 3: >40%. After allocation, infants were randomised 1:1 to treatment 
with tacrolimus ointment once or twice daily. Study V was an open 2-year non-
comparative multi-centre phase II safety study (Table 6).
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The study protocols for Studies I to V were approved by the local ethics committee at Helsinki 
University Central Hospital. All patients or their parents in Studies IV and V, gave written informed 
consent before the start of the study. The use of study medication, either tacrolimus ointment or the 
corticosteroid regimen (in Study II) was approved by the National Agency for Medicines 
(Lääkelaitos). 
Studies I and III were open, single-centre studies conducted in patients who were participating or 
had participated in a long-term multi-centre safety study of 0.1% tacrolimus ointment. Study II was 
a one-year double-blind randomised controlled study, where patients were treated with either 0.1% 
tacrolimus ointment or a corticosteroid regimen. Some of the efficacy and safety data from the first 
6 months of the study were included in a large multi-centre study (Reitamo et al 2005). Study IV 
was a randomised double-blind pharmacokinetic multi-centre study, in which patients were treated 
with 0.03% tacrolimus ointment either once or twice daily. Following enrollment, patients were 
allocated to three different groups depending on the affected body surface area (BSA): Group 1, 5 
to 20%, Group 2, >20 to 40%, and Group 3: >40%. After allocation, infants were randomised 1:1 to 
treatment with tacrolimus ointment once or twice daily. Study V was an open 2-year non-
comparative multi-centre phase II safety study (Table 6). 
 
Table 6. Study protocols         




I Open, controlled 0.1% tacrolimus !16 years 12 months 12 months 
II Double-blind, randomised 0.1% tacrolimus vs corticosteroid*  !18 years 12 months 12 months 
III Open, uncontrolled, follow-up 0.1% tacrolimus !13 years 48  months 10 years 
IV Double-blind, randomised 0.03% tacrolimus UID vs BID  3-24 months 14 days 18 days 
V Open, uncontrolled 0.03% tacrolimus  3 -24 months  24 months  24 months  
*hydrocortisone acetate for head and neck, hydrocortisone butyrate for trunk and limbs   




Patients in Study I were treated with 0.1% tacrolimus ointment for 12 months. Patients in Study III 
were during the 4-year intervention period treated with 0.1% tacrolimus ointment, but were after the 
study free to choose any type of AD treatment; these were registered at the 10-year follow-up visit. 
Study II was double-blind, with patients randomised (1:1) at baseline for either treatment with 0.1% 
tacrolimus ointment, or a corticosteroid regimen which included 1% hydrocortisone acetate 
ointment for the head and neck and 0.1% hydrocortisone butyrate ointment for the trunk and limbs. 




Patients in Study I were treated with 0.1% tacrolimus ointment for 12 months. 
Patients in Study III were during the 4-year intervention period treated with 0.1% 
tacrolimus ointment, but were after the study free to choose any type of AD treat-
ment; these were registered at the 10-year follow-up visit. Study II was double-
blind, with patients randomised (1:1) at baseline for either treatment with 0.1% 
tacrolimus ointment, or a corticosteroid regimen which included 1% hydrocor-
tisone acetate ointment for the head and neck and 0.1% hydrocortisone butyrate 
ointment for the trunk and limbs. The ointment tubes were identical in appearance 
in both groups. They were given to the patient and then returned to the investiga-
tor in sealed boxes, and thus the investigator could not assess the ointment bases. 
In Studies I to III, patients were advised to treat all lesions with study ointment 
twice daily until the end of itching and of any signs of eczema, and then for an 
additional 7 days to minimise possible subclinical inflammation. In Studies I and 
III, treatment was restarted if a new lesion occurred or if the disease recurred on a 
previously cleared lesion. In Study II, treatment was restarted in case of a flare-up. 
No restrictions were put on study drug usage. 
In Study IV, the area to be treated with study medication was defined on Day 1. 
During the 14-day study period, the treatment area could not be altered, regardless 
of any eczema healing or new lesions. At the Day 1 and 14 visits, patients received 
a single application of study medication in order to obtain full pharmacokinetic 
profiles. At the Day 4 visit, the morning application was performed in the hospital 
after drawing of blood, to obtain the trough level. On all other treatment days, the 
defined areas were treated twice daily. Patients were limited to 5 g or less ointment 
per application (10 g per day). 
In Study V, 0.03% tacrolimus ointment was applied twice daily to all affected skin 
lesions until healing—for up to 3 weeks. If necessary, treatment continued once 
daily thereafter. In case of an exacerbation of AD, twice-daily treatment with the 
study ointment was restarted. Total tacrolimus ointment use was unrestricted. 
2.2 study schedules
Study I was performed on some of the patients participating in a long-term open 
tacrolimus study initiated in November 1998. The first follow-up was one week 
after initiation of tacrolimus treatment, and then after 1, 3, 6, 9, and 12 months. 
After this study, visits continued every 6 months up to 48 months. Patients were 
tested for recall antigen reactions at baseline and after 12 months of treatment. 
Healthy controls were recruited among medical students and personnel from the 
Skin and Allergy Hospital and were tested once, within the same time-lines as the 
AD patients. Retesting was performed in nine randomly chosen controls after one 
year to investigate whether retesting had any additive effect on test results. 
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Study II was conducted during the years 2001 and 2002. After randomisation, vis-
its were performed after 1, 2, and 4 weeks, and then monthly up to 6 months. Then 
visit intervals increased to 3 months until the 12th month and the end of the study 
visit.
Study III was performed in patients who had participated in the long-term open 
tacrolimus study, applying the same study schedule. Patients who had participated 
in the lung histamine challenge test at baseline were contacted and asked to par-
ticipate in the 10-year follow-up study, which required one visit at the Skin and 
Allergy Hospital. The visits and respiratory assessments were, at baseline, conduct-
ed between October 1998 and January 1999, and at the 10-year follow-up, between 
October 2008 and early March 2009, and thus were not confounded by the pollen 
season. 
Study IV was conducted during 2003 and 2004. Patients attended the hospital four 
times after the screening visit: at baseline, and at days 4, 14, and 18. Tacrolimus 
treatment ended at day 14, and day 18 was a follow-up visit.  
Patients from Study IV who met the inclusion criteria could continue directly into 
Study V, which was conducted during 2003 to 2006. Study visits were carried out 
at baseline and week 2, and then monthly until month 6. Then visits were every 3 
months until the 24th month and end of the study visit.
 
2.3 efficacy and safety assessments
In Studies I and III, treatment response to tacrolimus ointment was assessed by 
evaluating affected BSA, which in Study I was determined at baseline and at month 
12, and in Study III at baseline, month 48, and at the 10-year follow-up. Adverse 
events were recorded throughout the 4-year tacrolimus study. Laboratory tests, in-
cluding haematology and serum chemistry, were assessed at the screening, at week 
1, and at month 6, and then every 6 months until study end. At the 10-year follow-
up visit, patients were asked for their medical history since the last visit in the open 
tacrolimus study, with a special focus on events affecting the skin or airways. 
In Study II, the treatment response to the study medication was assessed by the 
EASI, a validated method in clinical studies of AD (Barbier et al. 2004). It is a 
composite index, including an assessment percentage of BSA involved, and of ery-
thema, infiltration or papulation, or both, excoriation, and lichenification, each on 
a scale of 0 to 3 (Table 7). The modified EASI (mEASI) is similar to the EASI, but 
also considers the itching during the last 24 hours. From the EASI score, a separate 
score for the head and neck area, “the eczema score for head and neck”, was calcu-
lated. This, and the mEASI score are not yet validated scores. Physician’s and pa-
tient’s global evaluation of clinical response, and the response for the head and neck 
area compared to baseline (cleared, excellent improvement, marked improvement, 
moderate improvement, slight improvement, no appreciable improvement, worse) 
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were recorded at every study visit. Adverse events were recorded throughout the 
study. Blood for laboratory tests, including haematology and serum chemistry, was 
drawn at the screening, and at the month-3, -6, and -12 visits.
In Study IV, the treatment response was at every visit assessed by the EASI score 
and by the physician’s global evaluation of clinical response compared to baseline 
(cleared, excellent improvement, marked improvement, moderate improvement, 
slight improvement, no appreciable improvement, worse). Adverse events were re-
corded throughout the study. Laboratory blood tests, including haematology and 
serum chemistry, were assessed at the screening visit and on days 4 and 18. Blood 
tacrolimus concentrations were measured to estimate systemic exposure.
In Study V, the treatment response was assessed at every visit by the EASI score, 
affected BSA, and the physician and parent’s global evaluation of clinical response. 
Adverse events and laboratory parameters were monitored throughout the study. 
Tacrolimus blood concentration samples were collected at baseline, week 2, months 
1 and 3, and every third month thereafter. 
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Table 7. Eczema area and severity index: calculation for patients 8 years 
of age and older1      
Body region EASI Score2,3  
Head/Neck (H) (E + I + Ex + L) x Area x 0.1  
Upper limbs (UL) (E + I + Ex + L) x Area x 0.2  
Trunk (T) (E + I + Ex + L) x Area x 0.3  
Lower limbs (LL) (E + I + Ex + L) x Area x 0.4  
EASI= Sum of the above 4 body region scores   
1For children aged 0-7 years, proportionate areas were head/neck, 20%; 
upper limbs, 20%; trunk, 30%; and lower limbs, 30%.  
2E=Erythema, I=induration/papulation, Ex=excoriation, L=lichenification. 
3Where area is defined on a 7-point ordinal scale: 0=no eruption; 1=<10%; 
2=<10%-29%; 3=<30%-49%; 4=<50%-69%; 5=<70%-89%;   
6=>90%-100%.    




TEWL was measured in all patients in Study II at baseline and at months 3, 6, 9, and 12. 
Measurements were made at nine target regions (three on the upper limbs, two each on the head and 
trunk, and one on the neck and lower limbs) with an Evaporimeter EP1 (servoMed, Stockholm, 
Sweden) according to published guidelines (Pinnagoda 1990).  
$
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Recall antigen tests were performed with the Multitest CMI (Institute Mérieux, Lyon, France) 
applicator, which contained seven antigens: tetanus, diphtheria, Streptococcus group C, tuberculin, 
Candida albicans, Trichophyton, and Proteus, and glycerin as a negative control. The tests for each 
study (Studies I, II) came from the same batch. The Multitest applicator had eight prongs containing 
the antigens and the control, which were pressed into the skin on the volar side of the left forearm. 
If this site was affected by eczema, the other arm, or dorsal side was chosen. Topical treatment of 
the test site was not allowed in the morning before testing, nor before the reading of the test result 
48 hours later. A positive test reaction was defined as induration of at least 2 mm, and for these, 
average diameter (mm) was calculated. The results were analysed as the sum of average diameters 




2.4 Transepidermal water loss
TEWL was measured in all patients in Study II at baseline and at months 3, 6, 9, 
and 12. Measurements were made at nine target regions (three on the upper limbs, 
two each on the head and trunk, and one on the neck and lower limbs) with an 
Evaporimeter EP1 (servoMed, Stockholm, Sweden) according to published guide-
lines (Pinnagoda 1990). 
2.5 recall antigen testing
Recall antigen tests were performed with the Multitest CMI (Institute Mérieux, 
Lyon, France) applicator, which contained seven antigens: tetanus, diphtheria, 
Streptococcus group C, tuberculin, Candida albicans, Trichophyton, and Proteus, 
and glycerin as a negative control. The tests for each study (Studies I, II) came from 
the same batch. The Multitest applicator had eight prongs containing the antigens 
and the control, which were pressed into the skin on the volar side of the left fore-
arm. If this site was affected by eczema, the other arm, or dorsal side was chosen. 
Topical treatment of the test site was not allowed in the morning before testing, 
nor before the reading of the test result 48 hours later. A positive test reaction was 
defined as induration of at least 2 mm, and for these, average diameter (mm) was 
calculated. The results were analysed as the sum of average diameters (Merieux 
score) and as the number of positive antigens (Kniker et al 1979).   
2.6 serum ige and skin prick testing
In Study II, serum IgE samples were collected at baseline and at months 6 and 
12. In Study III, serum IgE samples were collected at baseline and at the 10-year 
follow-up visit. Samples were analysed by a fluorescence enzyme immunoassay 
(until the end of 2002: FEIA, CAP system; Pharmacia Diagnostics AB, Uppsala, 
Sweden; then by ImmunoCAP Total IgE, Phadia AB, Uppsala, Sweden), at the Skin 
and Allergy Hospital in Helsinki. Age-related references for the upper normal lim-
its are: age >17, 110 kU/L; 15 to 17, 160 kU/L; and 13 to 14, 320 kU/L (Björksten 
& Viander 1987).  
SPTs were performed on healthy skin on the forearms. Histamine dihydrochloride 
10 mg/ml served as the positive control, and saline as the negative. A test reaction 
of at least 3 mm was considered positive if the histamine reaction was at least 5 mm 
and the saline control negative. Antihistamines and antiemetic medications were 
withheld for 5 days prior to testing. In Study III, tests were performed for birch, 
timothy, mugwort, cat, dog, horse, cow, house dust mite, Cladosporium herbarum, 
and natural rubber latex at baseline. At the 10-year follow-up, the same allergens 
were tested, but only the standardised allergen extracts of timothy, mugwort, cat, 




2.7 respiratory symptoms and findings
Respiratory symptoms were evaluated at baseline and at the 10-year follow-up visit 
in Study III. Patients had, at the time of lung function testing and of answering the 
questionnaire, been free from respiratory tract infections for at least 2 weeks. 
2.7.1 Questionnaire 
All patients answered at baseline a validated questionnaire to estimate whether 
they had physician-diagnosed asthma or allergic rhinitis (Haahtela et al 1980). New 
asthma and rhinitis diagnoses were recorded at the follow-up visit. At the baseline 
and follow-up visits patients reported their degree of asthma (cough, wheesing, 
dyspnoea) and rhinitis symptoms during the previous month on a visual analogue 
scale (VAS) from 0 to 10 cm. A result of at least 2 cm was considered to represent 
active symptoms.  
2.7.2 Histamine challenge test
Lung function was measured with a pneumotachograph-based flow-volume 
spirometer (Masterscreen Pneumo, Jaeger GmbH, Würzburg, Germany). If the 
baseline forced expiratory volume in one second (FEV1) (Quanjer et al 1993) value 
was equal to or less than 60% of national predicted values (Viljanen et al 1982), 
no histamine challenge test was conducted. Use of short- and long-acting beta-
agonists was restricted for 1 vs 2 days, and of antihistamines and antiemetic medi-
cation for 5 days prior to the histamine challenge test.    
BHR was determined with a dosimetric histamine challenge test, where patients 
inhaled increasing doses of buffered histamine diphosphate (0.025, 0.1, 0.4 and 
1.6 mg) (Sovijärvi et al 1993). The dose of inhaled histamine producing a 15% de-
crease in FEV1 (PD15FEV1) was determined. Based on this dose, BHR was graded 
as no (>1.6 mg), mild (1.60-0.41 mg), moderate (0.40-0.11 mg), or severe (<0.10 
mg). From the PD15FEV1 dose and the decrease in FEV1, the slope of the dose-
response curve of the histamine challenge test was calculated, a continuous and 
normally distributed index (O’Connor et al 1987).
2.8 Tacrolimus pharmacokinetics
In Study IV, blood concentration-time profiles to define the pharmacokinetics of 
tacrolimus were collected after the first dose (day 1) and the last dose (day 14). 
Each profile consisted of serial samples collected before dosing and 2, 4, 8, and 24 
hours after the first application. An additional sample was taken at 96 hours after 
the day-14 application (day 18), and a single pre-dose blood sample was collected 
on day 4 to provide an estimate of exposure on that day while limiting the number 
of blood samples taken. The samples comprised 0.25 ml of blood placed in a tube 
containing EDTA as an anticoagulant, and immediately frozen and stored at -20 
ºC before being shipped to a central analytical laboratory.     
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Tacrolimus blood concentration was assayed by high-pressure liquid chromatogra-
phy (HPLC) with tandem mass spectrometry detection. Internal standard, a struc-
tural analog of tacrolimus and protein precipitation reagent (aqueous zinc sul-
fate solution, Sigma, Dorset, UK: methanol, Romil, Cambridge, UK: acetonitrile, 
Romil 50:30:20), was added to the samples. Solid-phase extraction (using 18C 
cartridges, Anachem, Luton, UK) of analytes was performed before injection onto 
the liquid chromatography mass spectrometer (Sciex API III Plus, PerkinElmer, 
Beaconsfield, UK). The lower limit of quantification for this method was 0.025 
ng/ml with a precision—based on the coefficient of variation—of less than 21.3% 
for the lowest quality control sample and less than 14.7% for all other concentra-
tions. All procedures were performed according to the Good Laboratory Practice 
guidelines. 
3. statistical methods
In Studies I to III, analyses were performed with SPSS versions 11.0, 13.0 or 15.0 
(SPSS Inc, Chicago, IL, USA). The results are expressed as the mean ± SD for nor-
mally distributed variables, and as the median (range or interquartile range) for 
non-normally distributed variables. Intention-to-treat analyses with the last ob-
servation carried forward were carried out where appropriate. A P-value of <0.05 
was considered statistically significant.
The material was mainly non-parametrically distributed due to relatively small 
patient numbers. The Wilcoxon test served to test differences before and after 
study treatment. Differences between the patients and controls (Study I), or the 
two different treatment groups (Study II) were tested with the Mann-Whitney test. 
Fisher’s exact test served for testing associations between binary variables. Binary 
values (yes/no) in a patient group before and after treatment (anergy, BHR) were 
compared with the McNemar test. In Study II, correlations between different vari-
ables were examined by Spearman’s correlation analysis. 
In Study III, the log slope of the dose response curve was tested by the paired t-
test. 
In Study IV, pharmacokinetic parameters were determined by noncompartmental 
analysis with the computer program WinNonlin Professional version 4 (Pharsight 
Corporation). Area under the curve (AUC) calculations were made by the linear/
logarithmic trapezoidal rule. The parameters determined were area under the con-
centration-time curve between first and last time-points, mean maximum serum 
concentration, time to attain maximum blood concentration, and terminal half-
life. Otherwise the statistical analyses in Studies IV and V were descriptive, and no 





The clinical efficacy of topical tacrolimus was very good in all studies. The im-
provement in affected BSA in study patients is presented in Figure 4. In Studies II, 
IV, and V, EASI scores were assessed in addition. 
In Study I, the mean affected BSA decreased from 32 to 8.8% after 12 months of 
treatment with 0.1% tacrolimus ointment.
 In Study II, affected BSA, EASI, and mEASI decreased in both the tacrolimus- and 
corticosteroid-treated patients at month 6 and month 12. The median EASI score 
decreased from 21.3 to 3.5 in the tacrolimus-treated patients, and from 20.1 to 6.4 in 
the corticosteroid-treated patients at month 12. The improvement in all scores was 
significantly greater (P≤0.05) in the tacrolimus-treated patients at month 6. After 
month 6, efficacy scores showed a slight improvement in the corticosteroid-treated 
patients, while the results in the tacrolimus-treated patients stayed approximately 
at month-6 level. No significant difference in the efficacy parameters between the 
groups was thus evident at the month-12 visit. At month 12, tacrolimus-treated 
patients showed an improvement of 91%, and corticosteroid-treated patients an 
improvement of 79% in median affected BSA. The eczema score for the head and 
neck was analysed separately from the EASI score, and was significantly lower in 
patients treated with tacrolimus ointment at both month 6 (P=0.001) and month 
12 (P<0.05). This was in accordance with the physician’s evaluation of head and 
neck clinical response at month 12; in the tacrolimus arm 24 of the 40 patients 
(60%) compared to 12 of 40 (30%) in the corticosteroid arm were rated as “cleared 
or excellent” (P<0.01). When the physician’s global evaluation of clinical response 
(which includes the whole body) at month 12 was done, 23 (57.5%) of tacrolimus-
treated, and 17 (42.5%) of the corticosteroid-treated patients were evaluated as 
“cleared or excellent” (P=0.26, ns). The median number of days in Study II was 
363 for the tacrolimus group and 361 for the corticosteroid group, and the median 
number of treatment days during the study was 255 for the tacrolimus- and 327 
for the corticosteroid group.
In Study III, median affected BSA decreased during the 10-year follow-up from 
19 to 1.6% (P<0.0001). Patients who responded (≥60% improvement of affected 
BSA, n=42) to intensive treatment with 0.1% tacrolimus ointment at the 1-year 
visit in the open safety study showed significantly less affected BSA at both the 
4-year visit (P<0.001) and the 10-year follow-up (P=0.04) compared to the non-
responders (<60% improvement, n=23). Responders and non-responders did not 
differ at baseline in terms of age, sex, disease severity, atopic sensitisations, or se-
rum IgE levels. 
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In Study IV, the median EASI score fell from 14.7 to 5.5. In Study V, the median 
EASI fell from 8.3 to 0.8, and for both this score and the aff ected BSA a continuous 
decrease was apparent throughout the study. Th e physician rated the global evalu-
ation of clinical response as “cleared” or “excellent” in 63.3% of the patients, and 
the parents assessed the symptoms as “much better” in 85.7% of the infants. Th e 
mean number of participation days in Study V was 623, with 28 treatment days 
during the fi rst month. 
Figure 4. Improvement of median aff ected BSA in the diff erent studies. 
tac=tacrolimus, BSA=body surface area
 
2. safety
Studies I and III did not investigate the safety of tacrolimus ointment, but were 
conducted in patients participating in an open 4-year study, which primarily inves-
tigated the safety and effi  cacy of 0.1% tacrolimus ointment (Reitamo et al 2008). 
In Study II, adverse events occurred in 40 patients (100%) in the tacrolimus oint-
ment group and in 34 patients (85%) in the corticosteroid group. Th e diff erence 
between groups was statistically signifi cant (P=0.03) and was mainly due to the 
higher incidence of skin burning with tacrolimus ointment. During the study, fl u 
syndrome was reported by 22 tacrolimus-treated and by 16 steroid-treated pa-
tients (P=0.26), and folliculitis by 20 vs 17 (P=0.65). No diff erence in infections 
occurred between groups (P=0.07). During the last 3 months of the study, two 
patients treated with the corticosteroid regimen showed signs of skin atrophy: one 
had striae of the legs and one subcutaneous haematomas. No patients showed any 
clinically signifi cant changes in serum chemistry or haematology; none suff ered 
from any serious adverse event. 
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Studies I and III did not investigate the safety of tacrolimus ointment, but were conducted in 
patients participating in an open 4-year study, which primarily investigated the safety and efficacy 
of 0.1% tacrolimus ointment (Reitamo et al 2008).  
In Study II, adverse events occurred in 40 patients (100%) in the tacrolimus ointment group and in 
34 patients (85%) in the corticosteroid group. The difference between groups was statistically 
significant (P=0.03) and was mainly due to the higher incidence of skin burning with tacrolimus 
ointment. During the study, flu yndrome was reported by 22 tacrolimus-treated and by 16 steroid-
tre ted p tients (P=0.26), a d folliculitis by 20 vs 17 (P=0.65). No difference in infections occurred 
between groups (P=0.07). During the last 3 months of the study, two patients treated with the 
corticosteroid regimen showed signs of skin atrophy: one had striae of the legs and one 
subcutaneous haematomas. No patients showed any clinically significant changes in serum 
chemistry or haematology; none suffered from any serious adverse event.  
In Study IV, the most common adverse events were infections such as upper respiratory tract 
infections and local skin irritations such as skin burning and pruritus. A total of 48 adverse events 
were reported in 35 patients (66%). Of these, 12 (23%) had at least one causally related adverse 
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In Study IV, the most common adverse events were infections such as upper respi-
ratory tract infections and local skin irritations such as skin burning and pruritus. 
A total of 48 adverse events were reported in 35 patients (66%). Of these, 12 (23%) 
had at least one causally related adverse event and 9 (17%) at least one application-
site adverse event. None suff ered from a serious adverse event nor showed any 
clinically signifi cant changes in their blood chemistry or haematology tests.   
In Study V, 47 patients (94%) had at least one adverse event during the whole 
2-year study. Th e most common adverse events were infections of the respiratory 
and gastrointestinal tracts, and the infections of the middle ear commonly seen in 
this age group. Two patients discontinued due to an adverse event, possibly related 
to tacrolimus ointment: one with an application-site skin infection and one with 
thrombocytopenia. A total of 19 serious adverse events occurred in 12 patients; of 
these one case of eczema herpeticum was considered to be related to treatment. 
No deaths occurred. Nor did any clinically signifi cant changes in the laboratory 
parameters occur during the study.
      
3. Transepidermal water loss
In Study II, both tacrolimus- and steroid-treated patients showed a TEWL de-
crease aft er 6 and 12 months of treatment for both the combined sites of head and 
neck, and trunk and limbs, when compared to baseline (P<0.001). TEWL for the 
head and neck at both the month-6 and -12 visits were signifi cantly lower in the 
tacrolimus group than in the steroid group (month 6, P=0.001; month 12, P=0.04), 
which was in accordance with the lower eczema scores for the head and neck in 
the tacrolimus group. TEWL for trunk and limbs showed no diff erence between 
groups. 
4. recall antigen testing
Patient characteristics and recall antigen results for Studies I and II are summarised 
in Table 8. In Study I, both the Merieux score and number of positive antigens were 
at baseline signifi cantly lower in the AD patients than in the healthy controls. Aft er 
one year of tacrolimus treatment, a signifi cant increase occurred in the reactions. 
Healthy controls, retested aft er one year (n=9), showed a decrease both in mean 
number of positive antigens (from 3.56 to 2.67) and in mean Merieux score (from 
13.8 to 7.7). 
In Study II, no increase in Mérieux score or in number of antigens was evident 
aft er 6 months of treatment in either tacrolimus- or corticosteroid-treated pa-
tients. Aft er one year of treatment, patients in both groups experienced a signifi -
cant increase in Mérieux score compared to baseline (tacrolimus P=0.001, steroid 
P=0.04). Th e number of positive antigens at month 12 increased signifi cantly only 
in the tacrolimus ointment group (P=0.003). In the corticosteroid regimen group 
the increase was numerical, but non-signifi cant (P=0.09). Th e diff erence between 
the groups at month 12 was non-signifi cant (P=0.46). Figure 5 shows the Merieux 
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score and Figure 6 the median number of antigens in tacrolimus-treated patients 
from Studies I and II.
An inverse correlation between the Merieux score and serum IgE was seen for all 
patients (n=80) at both baseline (R= -0.40, P<0.001), and month 12 (R= -0.34, 
P=0.002). 
In both Studies I and II, baseline anergy (no positive antigen reactions) was more 
common in severe disease than in moderate (P<0.01, Fisher’s exact test, and 
P=0.05, Chi-square test), but neither sex nor age affected anergy. In Study I, the 
number of anergic patients decreased significantly (P<0.001, McNemar test) after 
12 months of treatment. None of the control patients was anergic at baseline. In 
Study II, the number of anergic patients in the tacrolimus group decreased from 13 
at baseline to 6 at month 12, a non-significant decrease (P=0.065, McNemar test). 
In the corticosteroid group, those patients anergic decreased from 10 at baseline to 
7 at month 12 (P=0.45, McNemar test).
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Table 8. Patient characteristics and recall antigen results in Studies I and II.    










Baseline      
Number of patients 48a 28  40 40 
Age (years), mean  26.1 29.2  29.2 29.3 
Gender, male n (%) 17 (35.4) 10 (35.7)  9 (22.5) 10 (25.0) 
BSA affected, mean % 32.9 NA  54 56 
Moderate AD, n (%) 33 (68.8) NA  18 (45.0) 19 (47.5) 
Severe AD, n (%) 15 (31.3) NA  22 (55.0) 21 (52.5) 
Merieux score, median 3.75# 14.75  3 4 
Nr. of pos. antigens, median 1.00# 3.00  1 1.5 
Anergic patients, n 15 0   13 10 
Month 12      
Number of patients 45 9  40 40 
BSA affected, mean % 8,8 NA  19.7 24.4 
Merieux score, median 10.00*** 7.00*  7.00*** 5.00* 
Nr. of pos. antigens, median 3.00*** 2.00  2.00** 2 
Anergic patients, n 1 0   6 7 
aOne patient withdrew after 6 months, technical difficulties prevented recall antigen testing in two  
patients. BSA=body surface area; AD=atopic dermatitis; NA=not applicable. 
*P<0.05, **P<0.01, ***P<0.001 vs baseline; # P<0.001 vs control    








Figure 5. Merieux scores in patients treated with 0.1% tacrolimus ointment for 
one year in the double-blind study (Study II) and open-label study (Study I). * 
P≤0.001 vs baseline. Th e results are presented as box plots with the median value 
represented by a line across the box, the mean by a small black box, and minimum 
and maximum values by bars.  
Figure 6. Median number of positive antigens in patients treated with tacrolimus 
ointment for one year in the double-blind (Study II) and open-label (Study I) stud-
ies. #P=0.003 vs baseline, *P<0.0001 vs baseline. Bars represent the interquartile 
range.




Figure 5. Merieux scores in patients treated with 0.1% tacrolimus ointment for one year in the 
double-blind study (Study II) and open-label study (Study I). * P!0.001 vs baseline. The results are 
presented as box plots with the median value represented by a line across the box, the mean by a 
small black box, and minimum and maximum values by bars.   
 
Figure 6. Median number of positive antigens in patients treated with tacrolimus ointment for one 
year in the double-blind (Study II) and open-label (Study I) studies. #P=0.003 vs baseline, 
*P<0.0001 vs baseline. Bars represent the interquartile range. 




Figure 5. Merieux scores in patients treated with 0.1% tacrolimus ointment for one year in the 
double-blind study (Study II) and open-label study (Study I). * P!0.001 vs baseline. The results are 
presented as box plots with the median value represented by a line across the box, the mean by a 
small black box, and minimum and maximum values by bars.   
 
Figure 6. Median number of positive antigens in patients treated with tacrolimus ointment for one 
year in the double-blind (Study II) and open-label (Study I) studies. #P=0.003 vs baseline, 
*P<0.0001 vs baseline. Bars represent the interquartile range. 
resulTs
52
5. serum ige and skin prick testing
Both Studies II and III showed a decrease in serum IgE in patients with at least 
60% improvement of BSA. 
In Study II, median serum IgE values differed significantly between the groups at 
baseline (tacrolimus 659 kU/L, steroid 1523 kU/L, P=0.03), although other baseline 
characteristics like disease severity and affected BSA were comparable. A decrease 
in median serum IgE from 666 to 584 kU/L (P=0.02) occurred in patients with a 
good treatment response (≥60% improvement of BSA, n=53) at the month-12 vis-
it, when tacrolimus- and corticosteroid-treated patients were analysed together. In 
patients with an excellent treatment response (≥90% improvement, n=29), the de-
crease was even more significant (median S-IgE 532 vs 383 kU/L, P<0.01) (Figure 
7). When the treatment groups where examined separately, the serum IgE decrease 
approached at best only borderline significance (P=0.05 for corticosteroid treat-
ment and ≥60% improvement), probably due to small patient numbers. 
Figure 7. Serum IgE levels in patients with good (≥60% improvement) and excel-
lent (≥90%) treatment response at month 12 in Study II.
In this study we could show a positive correlation between serum IgE and affected 
BSA both at baseline (R=0.40, P<0.001) and at month 12 (R=0.49, P<0.001). A neg-
ative correlation appeared between serum IgE and recall antigens (Merieux score) 
at baseline (R=-0.40, P<0.001) and at month 12 (R=-0.34, P=0.002). Responder 
status (<60% improvement of affected BSA or ≥60% improvement of affected BSA) 
at month 12 correlated with baseline serum total IgE (R=0.27, P=0.01), but not 


























Baseline Month 6 Month 12
*
**
*P  = 0.02; **P  = 0.009 vs. baseline (Wilcoxon test)
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In Study III, when all patients who participated in the follow-up were analysed, 
median serum IgE decreased compared to baseline (663 to 593 kU/L, P<0.05). 
When treatment response at month 12 was considered, patients with a good treat-
ment response (≥60%) showed a significant drop in serum IgE at the 10-year fol-
low-up (926 to 559 kU/L, P=0.002), whereas patients with a poor response (<60%) 
showed an increase that was non-significant (641 to 913 kU/L, P=0.25). 
During follow-up, SPT results increased: the mean number of positive antigens 
from the baseline 2.72 (median 3.00, n=64) to a follow-up 3.03 (median 3.00, n=50) 
(P=0.004) and mean sum of positive reactions from 16.65 (median 14.50) to 18.88 
(median 17.00) (P<0.001). The histamine reactions remained stable at follow-up. 
The treatment response at the follow-up visit did not affect the SPT results.   
    
6. respiratory symptoms and findings
6.1 respiratory symptoms
Active asthma symptoms (≥2 cm on the VAS) were reported by 42% (27 of 64) of 
the patients at baseline and 20% (10 of 50) at follow-up (P=0.04). Active rhinitis 
symptoms (≥2 cm on the VAS) were reported by 52% (33 of 64) at baseline and 
by 36% (18 of 50) at follow-up (P=0.24, n.s.). In patients with active symptoms at 
baseline, the median values decreased significantly during follow-up, for asthma 
symptoms from 3.80 to 1.10 (P=0.02) and for rhinitis symptoms from 4.80 to 1.70 
(P=0.01).    
6.2 Histamine challenge test
BHR was at baseline seen in 33 of 64 (52%) patients and at the 10-year follow-up in 
21 of 50 (43%). Seven of the patients with BHR at baseline showed no airway reac-
tivity at follow-up, whereas four patients without BHR at baseline showed reactiv-
ity at follow-up (P=0.5, n.s.). Patients with BHR at baseline showed a significant 
increase in PD15FEV1 at the 10-year follow-up (P=0.02) indicating less BHR. The 
slope of the dose-response curve of the histamine challenge test showed a non-
significant decrease (indicating less BHR) in median values (0.0093 to 0.0075) 
(P=0.80). In patients with increased BHR at baseline, the median slope decreased 
from 0.0247 to 0.0186 (P=0.62, n.s.). FEV1 (l/s) and FEV1 (% of normal value), 
both decreased during the follow-up (P≤0.001).
7. Tacrolimus pharmacokinetics
In Study IV, 46 of the 53 patients had complete blood concentration-time pro-
files; pharmacokinetic analysis is based on their data (Table 9). Tacrolimus blood 
concentrations after application of 0.03% tacrolimus ointment was low. In 97% of 
the blood samples the tacrolimus concentrations were below 1 ng/ml, and in 20% 
of the samples undetectable. Still, samples showed increasing blood levels when 
treated BSA increased and with twice-daily compared to once-daily application. 
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The AUC time and mean maximum serum concentrations for the different groups 
based on treatment area, and once- vs twice-daily application are presented in 
Table 9 together with patient demographics. The trough (pre-dose) tacrolimus 
blood concentrations on day 4 were higher than on day 2, but on day 14 lower than 
on day 4. This suggests that, following treatment with 0.03% tacrolimus ointment, 
there occurred no systemic accumulation of tacrolimus. The elimination half-life 
of tacrolimus was measured after the last application on day 14 and varied among 
patients, but was, overall, similar in the three treatment groups, with a mean of 80 
± 35 h (range: 25-175 h). 
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Table 9. Patient demographics (pharmacokinetic evaluable set) and  
pharmacokinetic parameters of 0.03% tacrolimus ointment   
 Stratification group by treated BSA 
  5-20% >20-40% >40% 
Day 1    
Number of patients 16 13 17 
Age (months), mean ± SD 14.1 ± 5.4 12.2 ±5.9 16.6 ±5.1 
Gender, male/female 9/7 8/5 9/8 
Height, mean ± SD 77.9 ± 6.1 75.5 ± 5.7 80.5 ± 5.6 
Weight, mean ± SD 10.3 ± 1.9 9.5 ± 1.8 10.7 ± 1.7 
Caucasian, n (%) 15 (93.8) 12 (92.3) 15 (88.2) 
AUC0-24 , mean ± SD:    
UID treatment 1.07 ± 1.20 2.27 ± 1.70 8.43 ± 12.33 
BID treatment 1.21 ± 1.59 2.84 ± 2.45 9.45 ± 8.38 
Cmax , mean ± SD:    
UID treatment 0.07 ± 0.06 0.26 ± 0.33 0.64 ± 0.82 
BID treatment 0.10 ± 0.14 0.19 ± 0.12 1.15 ± 0.77 
Day 14    
AUC0-24, mean ± SD:    
UID treatment 1.61 ± 1.27 2.75 ± 1.98 7.25 ± 5.12 
BID treatment 3.13 ± 3.63 9.94 ± 5.65 14.63 ± 5.78 
Cmax, mean ± SD:    
UID treatment 0.10 ± 0.08 0.14 ± 0. 9 0.49 ± 0.48 
BID treatment 0.16 ± 0.16 0.48 ± 0.26 0.72 ± 0.28 
SD=standard deviation, AUC=area under the curve, UID=once daily,  






This thesis addresses four central areas in the treatment of AD with tacrolimus 
ointment. (1) Long-term efficacy and (2) safety are of major importance because 
AD is a chronic disease requiring long-term treatment strategies. Outcome for 
both long-term efficacy and safety is, however, dependent on the structural and 
functional effects of tacrolimus ointment on (3) the skin barrier. Skin barrier func-
tion seems also to be of major importance for (4) the development of airway dis-
ease in patients with AD. 
1. long-term efficacy
All studies (I-V) showed good long-term improvement of AD with topical tac-
rolimus treatment in accordance with earlier long-term studies in adults and chil-
dren (Remitz et al 2007, Reitamo et al 2008).
Study II is apparently the first double-blind study to compare treatment for one year 
with topical tacrolimus to treatment with a corticosteroid regimen in adults with AD. 
Both treatment groups showed excellent improvement of the eczema at month 12: 
Affected BSA decreased by 91% in tacrolimus-treated, and by 79% in corticosteroid-
treated patients. At month 6, tacrolimus treatment was significantly more effective than 
corticosteroid treatment (P≤0.05), consistent with the results from a 6-month, multi-
centre study which included almost 1000 patients (Reitamo et al 2005). Difference in 
treatment efficacy between the groups was non-significant at month 12, which was 
due to the continued improvement of eczema in the corticosteroid-treated patients. 
Although tachyphylaxis is a well-known phenomenon associated with topical corti-
costeroid treatment (du Vivier & Stoughton 1975), our findings found no evidence for 
it. Throughout the study, treatment response for the head and neck was significantly 
better in the tacrolimus-treated patients. The choice of a mild corticosteroid, hydro-
cortisone acetate, for treatment of this area can be criticised, but use of a more potent 
corticosteroid for one year could potentially lead to adverse events.  
In Study V, children under 2 years of age treated long-term with tacrolimus oint-
ment showed significant improvement of their eczema: both EASI and affected 
BSA improved more than 70%. No previous prospective long-term studies with 
topical tacrolimus treatment have apparently been conducted in this age group, 
but our efficacy results were similar to those in long-term studies of 2- to 15-year-
old children (Kang et al 2001, Remitz et al 2007). Our study was open, without 
blinding or a control group, which limits the interpretation of the efficacy results, 
since some of the children will outgrow their AD during their first years of life. 
Due to the known risks of long-term use of topical corticosteroids, a compara-
tive long-term study in this age-group is impossible. A vehicle-controlled study 
would, in fact, require effective rescue medication, since the children in Study V, 




AD starts before age 1 in 60% of the patients (Kay et al 1994), and these infants 
usually need treatment repetitively and over rather long periods. Use of emollients 
and avoidance of provocation factors like allergens and irritatives can help prevent 
eczema flares, but most will also need topical treatment for the skin inflammation. 
Infants and small children have higher relative BSA than do adults and enhanced 
penetration of topical corticosteroids (Turpeinen 1988) and might therefore more 
easily develop local side-effects like striae and steroid acne. Corticosteroid use in 
small children thus must be considered carefully, and treatment time restricted 
as much as possible. This can, on the other hand, lead to under-treatment of the 
eczema, which directly affects the child’s quality of life and that of the whole fam-
ily (Lewis-Jones et al 2001). Long-standing skin inflammation impairs the skin 
barrier, which may aggravate skin sensitisation to allergens and enable the atopic 
march. 
2. long-term safety
Results of the long-term double-blind study in adults treated with either tacrolimus 
ointment or a corticosteroid regimen (Study II) showed no long-term safety con-
cerns, except clinically visible skin atrophy, striae, and haematomas in two (5%) of 
the corticosteroid-treated patients. Although clinically visible skin atrophy occurs 
quite rarely, suppression of collagen synthesis can occur even in healthy controls 
after one week of treatment with a mild corticosteroid (Haapasaari et al 1995). The 
recovery of collagen synthesis is slow. When volunteers were treated for 3 days 
with betamethasone valerate, no recovery of collagen synthesis was evident after 
one corticosteroid-free week, and 2 weeks provided only 50% recovery (Haapasaari 
et al 1996). Other factors related to topical corticosteroid treatment, such as up-
regulation of proteases and breakdown of the corneodesmosomes, further impair 
the skin barrier in AD patients, and can lead to the rebound effect often occurring 
after corticosteroid treatment ends (Cork et al 2009). Treatment with tacrolimus 
ointment does not reduce skin collagen synthesis (Reitamo et al 1998); on the con-
trary, atrophy can be reversed by long-term tacrolimus monotherapy (Kyllönen et 
al 2004). No evidence reveals any direct effect of tacrolimus on collagen synthesis, 
so the increase in collagen synthesis is probably due to an effective treatment result 
or termination of corticosteroid treatment, or both.
In Study II, use of the study medication was unrestricted, and patients with mod-
erate-to-severe AD needed topical corticosteroid treatment for 327 of 361 study 
days to control their disease. Similar treatment has been applied in only one other 
1-year study (Luger et al 2004). Real-life treatment is usually more restricted to 
treat only major flares. In more severe disease, this restriction often leads to poorly 
controlled AD. Long-term, unrestricted treatment with topical corticosteroids in 
patients with moderate-to-severe AD leads to reduction in skin collagen synthesis 
with subsequent skin atrophy (Kyllönen et al 2004). 
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Other adverse events in the study were the well-known skin burning and alcohol 
intolerance in patients treated with tacrolimus ointment. Herpes simplex skin in-
fections occurred in six tacrolimus-treated patients (15%) compared to two corti-
costeroid-treated patients (5%). The difference between the groups was, however, 
non-significant, probably due to the small number of patients. The large 6-month 
multi-centre study with the same study setting showed a slight but significant 
increase in Herpes simplex skin infection incidence during the first months in 
tacrolimus-treated compared to the incidence in corticosteroid-treated patients. 
At the end, the incidence decreased and was comparable between these groups 
(Reitamo et al 2005).  
The 2-week pharmacokinetic study (Study IV) and the 2-year safety study (Study 
V) in children under age 2 revealed no new safety concerns. Systemic exposure to 
tacrolimus was low in both studies, with no evidence of systemic accumulation 
with repeated treatment. The 2-week study showed low systemic absorption also 
in patients with over 40% affected BSA, but a tendency towards increasing absorp-
tion when the treated BSA increased. Percutaneous absorption of hydrocortisone 
causes a higher rise in serum cortisol in children with severe dermatitis and in 
those under age 18 months (Turpeinen 1988). Absorption of tacrolimus ointment 
seems to be similar in various age-groups of children and in adults (Harper et al 
2005, Krueger et al 2007, Ruzicka et al 1997). Ex vivo studies in human skin have 
shown that rate of penetration for tacrolimus is low, and that the stratum corneum 
is the main rate-limiting barrier to its absorption (Undre 2004). This is probably 
due to the tacrolimus molecule’s highly lipophilic properties and large size (Billich 
et al 2004). Long-term safety of topical tacrolimus treatment in children under age 
2 should be studied in a comparative setting and long-term with a large number 
of children.         
3. structural and functional effects on the skin barrier
Study II showed improvement of the skin barrier function in terms of TEWL after 
6 and 12 months of treatment in both the tacrolimus and corticosteroid groups. 
No significant difference in TEWL was evident between the two treatment groups 
for the trunk and limbs, but TEWL for the head and neck was lower in patients 
treated with tacrolimus ointment at months 6 and 12. This was in accordance with 
the significantly lower eczema score for head and neck than for patients treated 
with topical corticosteroids. Skin barrier function in AD is impaired by gene-
tic factors, but also by active skin inflammation. In a severe flare of AD skin, the 
sources of proteases include inflammatory cells and S. aureus, both of which im-
pair the barrier function. The anti-inflammatory actions of topical corticosteroids 
can reduce production of these proteases, and will in a flare therefore improve 
barrier function. Before and after a flare, in fact, the main source of proteases in 
the stratum corneum is endogenous proteases such as the stratum corneum chy-
motryptic enzyme (kallikrein 7), which are further increased by the use of topical 
corticosteroids (Cork et al 2008). Tape-stripping of the skin in healthy controls 
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implies that treatment with topical corticosteroids also impairs the function of 
the corneodesmosomes; more corneocytes are removed from skin treated with 
topical corticosteroids than from skin treated with vehicle. The more corneocytes 
removed per tape strip, the higher the TEWL (Kao et al 2003). Even short-term 
corticosteroid treatment has elevated TEWL in healthy controls (Kolbe et al 2001). 
It is possible that tape-stripping of the skin before measuring TEWL in the double-
blind study could have revealed a greater difference between the tacrolimus- and 
corticosteroid-treated patients, but this must be confirmed in future studies.   
  
Cell-mediated immunity, studied with recall antigens in Study I, showed signifi-
cantly impaired reactions in patients with AD compared to reactions of healthy 
controls at baseline. After one year of tacrolimus treatment, recall antigen reactiv-
ity improved significantly and was close to that of the healthy controls. This cannot 
be due to increased reactivity through repeated exposure to the same antigen, as 
the reactivity decreased in control patients tested twice. In Study II, treatment with 
tacrolimus ointment or the corticosteroid regimen improved reactivity in terms of 
the Merieux score after 12 months, but no increase occurred in either group after 
6 months of treatment. Significant improvement of skin inflammation occurred in 
both treatment groups after 3 months of treatment, which indicates that improve-
ment of recall antigen reactivity is not a direct consequence of skin improvement. 
Effective, long-term anti-inflammatory treatment of AD improves the skin barrier 
and probably subsequently improves the Th1/Th2 imbalance in the skin, which 
in these studies was reflected as improved cell-mediated immunity. In contrast, 
systemic immunosuppressive treatment with ciclosporin reduces cell-mediated 
immunity (Ellis et al 1991).    
The same study also showed an inverse correlation between recall antigen reac-
tivity and serum IgE levels and confirmed a correlation between serum IgE levels 
and affected BSA or EASI, as reported by other authors (Laske & Niggemann 2004, 
Clendenning 1973). Patients (both tacrolimus- and corticosteroid-treated, analysed 
together) with at least 60% improvement of affected BSA showed a significant de-
crease in serum total IgE levels after one year of treatment. These data suggest that 
the best results in terms of reduction of serum IgE levels appear when the affected 
BSA is as small as possible, long-term. Long-term improvement of the skin barrier 
function in AD led to decreased Th2 activity and a decrease in serum IgE levels.  
4. effects on atopic airway disease
Study III included a 6-year follow-up after an initial 4-year intervention with tac-
rolimus ointment in patients with moderate-to-severe AD, and showed a signifi-
cant decrease in affected BSA, respiratory symptoms, and total serum IgE. The lack 
of a control group is a limitation of the study, since it is difficult to interpret the 
role of time and that of the initial 4-year intensive treatment. However, only a few 
longitudinal studies on respiratory symptoms in patients with AD are available, 
and this is, to our knowledge, the longest follow-up. 
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Patients with BHR at baseline revealed at the 10-year follow-up visit an increase 
in the histamine dose needed to induce a 15% decrease in FEV1, which indicates 
less BHR. They also reported significant improvement in their clinical asthma and 
rhinitis symptoms. As the BHR measurements and questionnaires were performed 
from October to early March, pollen-season effects were absent. These results are 
in accordance with those seen in the same patients after one year of tacrolimus 
treatment (Virtanen et al 2007). That study could in addition report a significant 
decrease in the log slope of the dose response curve, another way to report BHR. 
An increase in BHR in adults was reported in one 9-year longitudinal follow-up 
study, which found especially smoking to be a risk factor, but not atopy (Chinn et 
al 2005). 
A murine model of allergic asthma, using natural rubber latex as a model allergen, 
revealed that the skin is the most efficient route of sensitisation, whereas sensitisa-
tion through the airways fails to induce allergic asthma (Lehto et al 2005). Murine 
models have suggested two mediators involved in the pathogenesis and progres-
sion from AD to BHR. TSLP is an interleukin-7-like cytokine overexpressed in 
skin-barrier defects, with subsequent high systemic levels. This leads, after allergen 
challenge of the lungs, to BHR which can be blocked by elimination of TSLP signal-
ling (Demehri et al 2009). He and co-workers (2007) proposed IL-17 as a mediator 
of the atopic march; they found that initial cutaneous exposure to ovalbumin in 
mice induced the production of IL-17, which drove inflammation of the airways. 
In a murine model for allergic rhinitis, initial skin sensitisation and subsequent 
intranasal allergen challenge with the same aeroallergen provoked nasal inflam-
mation and BHR (Akei et al 2006). These animal models for the “atopic march” 
imply that development of BHR requires either initial sensitisation through the 
skin with an allergen, or an impaired skin barrier. By treating AD long-term and 
effectively with tacrolimus ointment it is possible to improve the skin barrier and 
most probably reduce sensitisation to allergens through the skin.     
5. ideal long-term treatment of atopic dermatitis
In the present studies (I-III), treatment with tacrolimus ointment was performed 
until all symptoms of AD including the itching had cleared, and thereafter for one 
additional week. Treatment was reintroduced when new symptoms appeared. This 
treatment modality differs from both the standard flare and preventive intermittent 
treatment modalities for AD (Wollenberg et al 2008, Thaçi et al 2008). Standard 
flare treatment of AD is based on topical corticosteroid treatment and focuses on 
flare treatment only, whereas preventive intermittent treatment means daily treat-
ment until milder disease or even clearing of symptoms is achieved; thereafter 
treatment of sites of previous lesions is given a few times weekly (Hanifin et al 
2002, Berth-Jones et al 2003). 
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Preventive treatment has shown better efficacy in preventing disease flares with 
both topical calcineurin inhibitors and corticosteroids in children and adults 
(Wollenberg et al 2008, Thaçi et al 2008, Breneman et al 2008, Paller et al 2008, 
Hanifin et al 2002, Berth-Jones et al 2003). Such studies have lasted less than 6 
months for corticosteroids, due to their long-term adverse events. Comparison of 
patients with similar disease severity (moderate to severe, according to the Rajka-
Langeland criteria) indicates that long-term results are very good both with the 
present treatment modality in Studies I to III and with preventive intermittent 
treatment. The results of standard flare treatment are not equally good regarding 
topical corticosteroids and tacrolimus ointment (Berth-Jones et al 2003, Reitamo 
& Allsopp 2009). The conclusion from these studies is to treat the patient until full 
recovery and then move gradually to intermittent treatment in such a way that no 
disease relapses occur. The present studies have shown that this approach can re-
sult in a reversal of the atopic march with improvement of skin symptoms, recov-
ery from the Th1/Th2 imbalance, and improvement of the atopic airway disease 
symptoms. As treatment with tacrolimus ointment does not seem to be hampered 
by long-term adverse events, this goal can be achieved with good patient informa-
tion and instruction, which leads to better compliance. The present studies in chil-
dren under age 2 also suggest that long-term treatment with tacrolimus ointment 




Long-term treatment with tacrolimus ointment in patients with AD shows good 
efficacy and safety, not only in patients over age 13, but also in infants aged over 3 
months. The main advantage of topical tacrolimus monotherapy treatment com-
pared to topical corticosteroids for AD is that it causes no skin atrophy and thus 
allows better improvement of the epidermal barrier function. Improvement of the 
skin barrier function and reduction in skin inflammation leads to normalisation 
of the cell-mediated immunity of the skin. This results, over time, in a decreased 
incidence of bacterial and viral skin infections. Normalisation of the Th1/Th2 im-
munity results in a decrease in total serum IgE levels, which probably play a trig-
gering role for flares and also for symptoms of asthma. In development of BHR, 
the importance of skin barrier dysfunction and sensitisation through the skin is 
supported by several murine studies. Improvement in atopic sensitisation and res-
piratory diseases associated with AD can possibly result from effective treatment 
of the skin barrier dysfunction. It may therefore be important to treat infants with 
AD effectively to improve barrier function. Future intervention studies should 
collect more information on the pathogenesis of AD and respiratory disease and 
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